

**ADDIS ABABA UNIVERSITY**  
**SCHOOL OF GRADUATE STUDIES**



***IN-VIVO ANTI-INFLAMMATORY ACTIVITY OF THE LEAF EXTRACTS AND  
FRACTIONS OF OCIMUM SUAVE IN MICE MODEL***

***BIRHANETENSAY MASRESHA***

***October 2011***

***Addis Ababa***

In-vivo anti-inflammatory activity of the leaf extracts and fractions of  
*Ocimum suave* in mice model

A thesis submitted to the School of Graduate Studies, Addis Ababa University in partial fulfillment of the requirements for the Degree of Master of Science in Pharmacology in the Department of Pharmacology, School of Medicine

By

Birhanetensay Masresha (B.Pharm)

Under the direct supervision of Prof. Eyasu Makonnen, Department of Pharmacology, School of Medicine, Addis Ababa University and Dr. Asfaw Debella, Directorate of Traditional and Modern Medicine, Ethiopian Health and Nutrition Research Institute

October 2011

Addis Ababa

## **ACKNOWLEDGMENTS**

First of all I praise the name of the **ALMIGHTY GOD** for being with me throughout my life endeavor.

I would like to extend my deepest gratitude and appreciation to my advisors Prof. Eyasu Makonnen and Dr. Asfaw Debella for their constructive advises, correction of the manuscript which help for the effective accomplishment of this work.

Special thanks also go to the Directorate of Traditional and Modern medicine, Ethiopian Health and Nutrition Research Institute (EHNRI) for facilitating part of the research work to be carried out in their laboratory and Addis Ababa University for sponsoring my M.Sc study. My special appreciation further goes to the staff members of the Department of Pharmacology, School of Medicine, Addis Ababa University for their support during my entire work.

Last but not least, I would like to express my affection and gratitude to all my friends and my family.

# TABLE OF CONTENTS

|   | <b>Page</b> |
|---|-------------|
| Acknowledgments.....                                | i           |
| Contents.....                                       | ii          |
| List of Tables.....                                 | iv          |
| List of Figures .....                               | v           |
| Abbreviations and Acronyms.....                     | vi          |
| Abstract .....                                      | vii         |
| 1. Introduction .....                               | 1           |
| 1.1. Inflammation.....                              | 1           |
| 1.1.1. Prevalence of Inflammatory Diseases.....     | 2           |
| 1.1.2. Chemical Mediators of Inflammation.....      | 4           |
| 1.1.3. Anti-inflammatory Drugs .....                | 11          |
| 1.2. Medicinal Plants .....                         | 15          |
| 1.2.1. Plants with Anti-inflammatory Activity ..... | 16          |
| 1.3. Ocimum suave .....                             | 18          |
| 2. Objectives.....                                  | 21          |
| 2.1. General Objective .....                        | 21          |
| 2.2. Specific Objectives .....                      | 21          |

|   |    |
|---|----|
| 3. Materials and Methods .....  | 22 |
| 3.1. Materials .....  | 22 |
| 3.1.1. Collection of Plant Materials .....                                | 22 |
| 3.1.2. Chemicals and Solvents .....                                       | 22 |
| 3.1.3. Experimental Animals .....   | 22 |
| 3.2. Methods .....  | 23 |
| 3.2.1. Preparation of Crude Extract .....                                 | 23 |
| 3.2.2. Preparation of Solvent Fractions.....                              | 23 |
| 3.2.3. Testing Anti-inflammatory Activity .....                           | 23 |
| 3.2.3.1. Carrageenan-induced Paw Edema .....                              | 23 |
| 3.2.3.2. Histamine-induced Paw Edema .....                                | 24 |
| 3.2.3.3. Serotonin-induced Paw Edema .....                                | 25 |
| 3.2.4. Statistical Analysis.....  | 25 |
| 4. Results .....  | 26 |
| 4.1. Effects of <i>Ocimum suave</i> on Carrageenan-induced Paw Edema..... | 26 |
| 4.2. Effects of <i>Ocimum suave</i> on Histamine-induced Paw Edema.....   | 29 |
| 4.3. Effects of <i>Ocimum suave</i> on Serotonin-induced Paw Edema.....   | 31 |
| 5. Discussion .....   | 34 |
| 6. Conclusion and Recommendation.....                                     | 37 |
| References.....   | 38 |

## LIST OF TABLES

|   | <b>Page</b> |
|---|-------------|
| Table 1: Effects of oral ethanol and aqueous extracts of <i>Ocimum suave</i> on carrageenan induced mouse paw edema.....  | 26          |
| Table 2: Anti-inflammatory activities of ethanol and aqueous extracts of <i>Ocimum suave</i> in comparison to that of aspirin on carrageenan-induced mouse paw edema..... | 27          |
| Table 3: Effects of oral butanol and water fractions of <i>Ocimum suave</i> on carrageenan induced mouse paw edema.....   | 28          |
| Table 4: Anti-inflammatory activities of butanol and water fractions of <i>Ocimum suave</i> in comparison to that of aspirin on carrageenan- induced mouse paw edema..... | 29          |
| Table 5: Effects of oral butanol and water fractions of <i>Ocimum suave</i> on histamine induced mouse paw edema.....   | 30          |
| Table 6: Anti-inflammatory activities of butanol and water fractions of <i>Ocimum suave</i> in comparison to that of aspirin on histamine-induced mouse paw edema.....    | 31          |
| Table 7: Effects of oral butanol and water fractions of <i>Ocimum suave</i> on serotonin induced mouse paw edema.....   | 32          |
| Table 8: Anti-inflammatory activities of butanol and water fractions of <i>Ocimum suave</i> in comparison to that of aspirin on serotonin-induced mouse paw edema .....   | 33          |

## LIST OF FIGURE

|  | <b>Page</b> |
|--|-------------|
| Figure 1: Eicosanoids biosynthesis from AA ..... | 5           |

## ABBREVIATIONS AND ACRONYMS

|                  |  |
|------------------|--|
| AA               | Arachidonic acid                               |
| AMP              | Adenosine monophosphate                        |
| BK               | Bradykinin                                     |
| COX              | Cyclooxygenase                                 |
| Cys-LTs          | Cysteinyl Leukotrienes                         |
| GM-CSF           | Granulocyte-Monocyte Colony Stimulating Factor |
| HETEs            | Hydroxyeicosatetraenoic acids                  |
| HRs              | Histamine receptors                            |
| ICAM-1           | Intracellular Cell Adhesion Molecule           |
| IFN              | Interferon                                     |
| IL               | Interleukin                                    |
| LOX              | Lipoxygenase                                   |
| LT               | Leukotrienes                                   |
| LXs              | Lipoxins                                       |
| NO               | Nitric oxide                                   |
| NOS              | Nitric oxide Synthase                          |
| NSADs            | Non Steroidal Anti-inflammatory Drugs          |
| PAF              | Platelet Activating Factor                     |
| PDE <sub>4</sub> | Phosphodiesterase E <sub>4</sub>               |
| PG               | Prostaglandin                                  |
| PLA <sub>2</sub> | Phospholipase A <sub>2</sub>                   |
| PMNs             | Polymorphonuclear cells                        |
| TGF- $\beta$     | Transforming Growth Factor                     |
| TM               | Traditional Medicine                           |
| TNF- $\alpha$    | Tumor Necrosis Factor                          |
| TXs              | Thromboxanes                                   |
| VCAM             | Vascular Cell Adhesion Molecule                |
| WHO              | World Health Organization                      |
| 5-HPETE          | 5-Hydroperoxyeicosatetraenoic acid             |
| 5-HT             | 5-Hydroxytryptamine                            |

## ABSTRACT

*Ocimum suave* has been used in Ethiopian traditional medicine to relieve pain, fever, inflammation and possibly other diseases conditions. Although there are some reports on analgesic, antipyretic, antiulcer, antimicrobial and wound healing effects, no study has been made regarding its possible anti-inflammatory effect. The objective of the present study was, therefore, to investigate ethanol and aqueous extracts and fractions (butanol and water residue) of the aqueous extract of the plant material. The ethanol and aqueous extract were screened for their anti-inflammatory activities on carrageenan-induced mouse paw edema at three dose levels 400, 600 and 800mg/Kg. The butanol and water fractions of the aqueous extract were also investigated for their anti-inflammatory activities on carrageenan, histamine and serotonin-induced mouse paw edema at three dose levels 50, 100, 200mg/Kg. Normal saline and aspirin (200mg/Kg) were employed as negative and positive control groups, respectively. Both ethanol and aqueous extracts significantly decreased carrageenan-induced inflammation at all doses used. Greater paw edema inhibition was, however, observed by the aqueous extract than ethanol one at 600 and 800mg/Kg dose levels. Similarly, both butanol and water fractions also showed significant reduction of inflammation induced by carrageenan, histamine and serotonin in mice paw. Highest inhibition, however, was exhibited by the aqueous fraction at 100mg/Kg and 200mg/Kg dose levels. From the present findings, it can be concluded that the extracts and fractions of the plant material have got anti-inflammatory properties. Thus the results support the traditional use of this plant in inflammatory conditions. Further investigation, however, should be pursued to identify the exact mechanism (s), isolate the bioactive principle (s) responsible for the anti-inflammatory action and others.

## **1. INTRODUCTION**

### **1.1. Inflammation**

Inflammation is considered immunological defense mechanism that is elicited in response to mechanical injuries, burns, microbial infections, allergens and other noxious stimulus (Yoon and Baek, 2005). The inflammatory response is a highly regulated biological process that enables the immune system to efficiently remove the injurious stimuli and initiate the healing process. It also establishes memory that enables the host to mount a faster and more specific response upon a future encounter, which leads ultimately to the restoration of tissue structure and function (Kular et al., 2011; Stables and Gilroy, 2011).

The process of inflammation is necessary in healing wounds. However, uncontrolled and persistent inflammation contributes to the progression of many chronic pathological conditions, such as rheumatoid arthritis, atherosclerosis, psoriasis, inflammatory bowel disease, retinitis, multiple sclerosis etc. (Kular et al., 2011; Talwara et al., 2011). It may also be associated with increased risk of cancer (Coussens and Werb, 2002; Schwab and Serhan, 2006; Mantovani et al., 2008; Aggarwal and Gehlot, 2009).

Inflammation could either be acute or chronic. The acute inflammatory response involves a complex series of events, including dilatation of arterioles, venules, and capillaries with increased vascular permeability, exudation of fluids including plasma proteins, and leukocyte migration into the inflammatory sites (Cirino, 1998; Delves and Roitt, 2002; Calder, 2006). This response produce the cardinal signs of inflammation redness (rubor), heat (calor), swelling (tumor), pain (dolor) and loss of function (De las Heras and Hortelano, 2009). It is a short-term response that usually results in healing process (Weiss, 2008).

The acute phase begins with the production of soluble mediators by resident cells in the injured or infected tissue that promote the exudation of proteins and influx of granulocytes from the blood. The leukocytes, typically neutrophils, phagocytose and eliminate foreign microorganisms. This process is followed by an event accompanied by active anti-inflammatory and pro-resolution processes (Stables and Gilroy, 2011).

In the chronic phase, inflammation is characterized by the development of specific humoral and cellular immune responses to the pathogens present at the site of tissue injury (Feghali and Wright, 1997). It is a prolonged, dysregulated and maladaptive response that involves active inflammation, tissue destruction and attempts at tissue repair (Weiss, 2008; Leitch et al., 2009). This phase involves infiltration of mononuclear immune cells: monocytes, macrophages, lymphocytes, and plasma cells (De las Heras and Hortelano, 2009).

Inflammatory process involves synthesis and release of local inflammatory mediators, such as prostaglandins (PGs), leukotrienes (LTs) and platelet activating factor (PAF) induced by phospholipase A<sub>2</sub> (PLA<sub>2</sub>), cyclo-oxygenase (COXs) and lipo-oxygenase (LOXs) (Omoigui, 2007; Venkatesha et al., 2011). Besides, other important inflammatory mediators including chemokines, cytokines, vasoactive amines, kinins, nitric oxide (NO) are also released during inflammatory process (Omoigui, 2007; De las Heras and Hortelano, 2009; Dinarello, 2010).

### **1.1.1. Prevalence of Inflammatory Diseases**

Unregulated inflammation can lead to persistent tissue damage and leads to a variety of inflammatory disorders. These include: rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, multiple sclerosis, psoriasis, asthma, atopic dermatitis etc. (Nathan, 2002; Ward and O'Neill, 2003).

Osteoarthritis and rheumatoid arthritis are the most prevalent causes of disability in western countries (Bertolini et al., 2001). Rheumatoid arthritis commonly results in joint destruction and significant impairment in the quality of life of the patients. Population-based studies showed that rheumatoid arthritis affects 0.5-1.0% of adults, with 5-50 per 100000 new cases annually in developed countries. This disease is 2 to 3 times more common in women than in men and can start at any age, but most commonly starts in middle adult life (Quan et al., 2008; Scott et al., 2010).

Prevalence of rheumatoid arthritis varies geographically. The disease is common in Northern Europe and North America compared with parts of the developing world, such as rural West Africa (Scott et al., 2010). Studies from south European countries also suggested a relative

lower occurrence of rheumatoid arthritis when compared with North European and North American countries (Alamanos et al., 2006). In general, the prevalence of the disease appears to be lower in developing countries (Mody, 2008).

Osteoarthritis is a progressive rheumatic diseases characterized by loss of joint cartilage that leads to pain and loss of function primarily in the knees and hips. It affects 9.6% of men and 18% of women aged more than 60 years. Increases in life expectancy and aging populations are expected to make osteoarthritis the fourth leading cause of disability by the year 2020 (Gautam and Jachak, 2009).

Asthma is a major public-health problem whose prevalence is increasing in most developed countries. Allergic diseases including asthma are reported to be low in rural subsistence and economically developing communities, and they increase with adoption of Western lifestyle (Yemaneberhan et al. 1997; Tattersfield et al., 2002).

Prevalence of wheeze and asthma has great geographical variation. The reported prevalence of wheezing illness in Western countries varies from as low as 5% in Sweden to as high as 25–30% in Australia and New Zealand. Data from developing countries also show wide variation: 0.007% in Papua New Guinea, 3.3% in rural Tanzania, 9.8% in urban Abidjan, 11.4% in Nairobi, and 20% in the Maldives (Hailu et al., 2003).

Prevalence data concerning asthma in Ethiopia is limited. Yemaneberhan *et al.* (1997) reported a 3.6% and 1.3% prevalence of asthma in urban and rural Jimma, respectively. All respiratory symptoms were rare in children and significantly less common in the rural community. Rosenberg *et al.* (1999) reported asthma rates of 2.5% among Ethiopian Jews at the time of immigration to Israel, with an increase to about 17% after 8–17 years in their new country.

Epidemiological data concerning skin inflammatory diseases in many rural sub-Saharan Africa is scarce. However, the limited data available indicates that inflammatory skin diseases represent the most frequent causes of morbidity in developing countries. The case is no different in Ethiopia where both hospital and population-based studies revealed that

inflammatory skin disorders are the leading causes of morbidity in the country with the prevalence estimates of about 50–70% (Yonathan et al., 2006).

### **1.1.2. Chemical Mediators of Inflammation**

Different types of mediators are released during inflammatory processes. These mediators can be derived from plasma proteins or secreted by cells (Medzhitov, 2008). Inflammatory mediators that can be involved in inflammatory reaction include: histamine, 5-HT, kinins, complement components, fibrin degradation product, lipid mediators (eicosanoids and PAF), cytokines, chemokines, proteolytic enzymes and NO (White, 1999; Medzhitov, 2008).

#### **Eicosanoids**

Arachidonic acid (AA)-derived eicosanoids belong to a complex family of lipid mediators that regulate a wide variety of physiological responses and pathological processes. Although originally recognized for their capacity to elicit biological responses, such as vascular homeostasis, protection of the gastric mucosa and platelet aggregation, eicosanoids are now understood to regulate immunopathological processes ranging from inflammatory responses to chronic tissue remodeling, cancer, asthma, rheumatoid arthritis and autoimmune disorders (Harizi et al., 2008; Haeggström et al., 2010).

Eicosanoids, including PGs, TXs, LTs and LXs, are signalling molecules that are generated primarily through an oxidative pathway from AA (Serhan and Chiang, 2008; Huwiler and Pfeilschifter, 2009). Unlike histamine, eicosanoids are not preformed in cells but are generated on demand (Rang et al., 2003).

The biosynthesis of eicosanoids depends on the availability of free AA. When tissues are exposed to diverse physiological and pathological stimuli, such as growth factors, hormones or cytokines, AA is produced from membrane phospholipids by the action of PLA<sub>2</sub> enzymes and can then be converted into different eicosanoids. AA can be enzymatically metabolized by three main pathways: Cytochrome P450 epoxygenase, COXs and LOXs (Figure 1). The P450 epoxygenase pathway produces HETEs and epoxides. The COX-1 and COX-2 generate PGs

and TXs; LOXs produce LTs and lipoxins (LXs) (Rolin et al., 2006; Harizi et al., 2008; Medzhitov, 2008).




Fig.1: Eicosanoids biosynthesis from AA (Harizi et al., 2008).

Prostanoids are the end products of the metabolism of AA by COX, PG synthases, and TX synthase (Harris et al., 2002; Rolin et al., 2006; Huwiler and Pfeilschifter, 2009). These synthases include PGD synthase, PGE synthase, PGF synthase, PGI synthase, and TXA synthase, which form PGD<sub>2</sub>, PGE<sub>2</sub>, PGF<sub>2α</sub>, PGI<sub>2</sub> (prostacyclin) and TXA<sub>2</sub>, respectively (Stables and Gilroy, 2011).

COX is a key enzyme in the biosynthesis of prostanoids from AA (Bertolini et al., 2001). In mammalian cells, COX exists in at least two isoforms: COX-1 (encoded by a constitutively expressed gene) and COX-2 (encoded by an immediate early response gene) (Harizi et al.,

2008; Stables and Gilroy, 2011), one variant form (COX-3) has been reported as well (Yoon and Baek, 2005).

COX-1 is constitutively expressed and responsible for basal production of prostanoids whereas COX-2 is inducible in response to different inflammatory stimuli such as endotoxin, IL-1 $\beta$ , and TNF- $\alpha$  (Hseu et al., 2005; Rolin et al., 2006). COX-1 is expressed in most mammalian cells under physiological conditions, and particularly large amounts are produced by endothelial cells, platelets, and kidney tubule cells. It has been shown that COX-2 is also constitutively expressed in the developing kidney and brain, playing a role in their maturation and function (Dannhardt and Kiefer, 2001; Ulbrich et al., 2002). Generally, COX-1 is involved in cellular housekeeping functions necessary for normal physiological activity whereas COX-2 participates in inflammation (Harris et al., 2002; Ulbrich et al., 2002).

Prostanoids are generated in most tissues and cells, modulating biological processes such as smooth muscle tone, vascular permeability, hyperalgesia, fever and platelet aggregation (Stables and Gilroy, 2011). PGE<sub>2</sub> and PGI<sub>2</sub> are the predominant pro-inflammatory prostanoids (Huwiler and Pfeilschifter, 2009). Both enhance vasodilation, oedema formation and vascular permeability particularly in the presence of histamine, bradykinin (BK) and 5-HT (Dannhardt and Kiefer, 2001; Rolin et al., 2006). PGE<sub>2</sub> is also the most potent pyretic agents and causes inflammatory pain (Dannhardt and Kiefer, 2001). Recent works demonstrated that PGI<sub>2</sub> also presents anti-inflammatory properties (Ley, 2008). In addition, PGD<sub>2</sub> is known to be associated with inflammatory conditions (Rolin et al., 2006).

Prostanoids exert their biological effects by binding to specific cell-surface receptors. There are at least nine known prostanoid receptors: the PGD receptors DP1 and DP2, the PGE<sub>2</sub> receptors, EP1, EP2, EP3 and EP4; the PGF receptor, FP; the PGI receptor, IP; and the TXA receptor, TP. All belong to the G-protein coupled receptor super-family (Rang et al., 2003).

LTs are end products of the metabolism of AA by 5-LOX. They are produced by various types of cells including mast cells, basophils, eosinophils, neutrophils, macrophages, monocytes (White, 1999; Kay, 2001). The first active intermediate derived from 5-LOX action is 5-HPETE which is further converted by synthases to the unstable LTA<sub>4</sub>. Then LTA<sub>4</sub> may either

be converted to  $\text{LTB}_4$  by a  $\text{LTA}_4$  hydrolase, or may be conjugated with glutathione yielding  $\text{LTC}_4$  by a  $\text{LTC}_4$  synthase. Successive amino acid cleavage of  $\text{LTC}_4$  yields  $\text{LTD}_4$  and then  $\text{LTE}_4$  (Rådmark and Samuelsson, 2010).  $\text{LTC}_4$ ,  $\text{LTD}_4$ , and  $\text{LTE}_4$  are collectively known as cysLTs because of the presence of a thioether-linked peptide (Fiorucci et al., 2001).

LTs act through four subtypes receptors, BLT-1, BLT-2, cysLT1, and cysLT2. They have physiological roles in innate immune responses and pathological roles in a variety of inflammatory and allergic diseases, such as rheumatoid arthritis, inflammatory bowel disease, allergic rhinitis, but most prominently in bronchial asthma. More recently, LTs have also been associated with atherosclerosis, osteoporosis and cancer (Huwiler and Pfeilschifter, 2009).

LTs are potent mediators of inflammation. For example  $\text{LTB}_4$  causes: neutrophil, eosinophil, lymphocyte and monocyte chemotaxis; neutrophil and eosinophil aggregation; induction of neutrophil degranulation and lysosomal enzyme release; induction of neutrophil–endothelial cell adhesion; and modulation of pain induced by inflammatory reactions (Bertolini et al., 2001). Cys-LTs cause bronchial smooth muscle contraction and induce synthesis and release of other pro-inflammatory mediators such as IL-8, PAF, and known to have role in pathogenesis of asthma (Fiorucci et al., 2001; Rang et al., 2003).

There are other groups of lipid mediators, pro-resolving lipid mediators including LXs, resolvins, and protectins which are involved in inflammation (Serhan, 2008). LXs ( $\text{LXA}_4$ ,  $\text{LXB}_4$ ) are generated from AA by 15-LOX enzyme (Rang et al., 2003). They act to reduce inflammation and promote resolution. Resolvins and protectins are derived from omega-3 polyunsaturated fatty acid and they possess potent anti-inflammatory, neuroprotective and pro-resolving properties (Schwab and Serhan, 2006).

LXs were shown to exert their anti-inflammatory and pro-resolution effects through stopping infiltration and activation of PMNs, reducing the synthesis of the pro-inflammatory  $\text{TNF-}\alpha$  and IL-8 and up-regulating the synthesis of anti-inflammatory  $\text{TGF-}\beta$  (Serhan, 2008; Huwiler and Pfeilschifter, 2009).

### **Platelet activating factor**

PAF is an ether-linked phospholipid. It is generated by the acetylation of lysophosphatidic acid. PAF may be produced by several types of cells that participate in the inflammatory response including mast cells, macrophages, neutrophils, and eosinophils. It activates several processes that occur during the inflammatory response such as, recruitment of leukocytes, vasodilation, increased vascular permeability and platelet activation (White, 1999; Medzhitov, 2008).

### **Complement fragments**

The complement system is a system of serine proteases which has role in host defense. Many complement products are pro-inflammatory. The complement fragments C3a, C4a and C5a are produced by several pathways of complement activation. C5a (and to a lesser extent C3a and C4a) promote granulocyte and monocyte recruitment and induce mast-cell degranulation (Gabay and Kushner, 1999; Ley, 2008).

### **Histamine**

Histamine is a low molecular weight amine which is an important chemical mediator in physiological and pathological responses. The biological functions of histamine are mediated through G protein-coupled histamine receptors (HRs) including, H1R, H2R, H3R and H4R (Schneider et al., 2002; Zhang et al., 2007).

Histamine is a potent mediator of immediate hypersensitivity reactions and thus known to trigger allergic reactions such as anaphylaxis (Kay, 2001; Passani and Blandina, 2011). It is stored primarily in mast cells and basophils (Jadidi-Niaragh and Mirshafiey, 2010). Besides, histamine is also found in gastric enterochromaffin – like cells, and histaminergic nerves in the brain (MacGlashan, 2003). Histamine is a pro-inflammatory agent and has different effects in the body, causing increased vascular permeability and vasodilation, neutrophil and eosinophil chemotaxis and inflammatory mediator release (Jadidi-Niaragh and Mirshafiey, 2010).

## **Nitric oxide**

Nitric oxide (NO) is a highly reactive free radical gas that is freely diffusible across membrane. It is synthesized and utilized by a variety of mammalian cells (Bishop and Anderson, 2005). NO is produced by the conversion of L-arginine to L-citrulline (Redington, 2006) via three different types of nitric oxide synthases (NOS) (Chatterjee and Catravas, 2008). Two of the isoforms endothelial (eNOS or NOS-3) and neuronal (nNOS or NOS-1) are expressed constitutively and responsible for the small amounts of NO production whereas the inducible isoform (iNOS or NOS-2) is expressed in response to a host of inflammatory stimuli such as bacterial products, cytokines, and lipid mediators to produce high amounts of NO (Redington, 2006; Blaise et al., 2007).

Studies showed that NO has role in the modulation of a variety of acute and chronic inflammatory disorders (Laroux et al., 2000). NO is generated at high levels during inflammatory reactions such as asthma and sepsis. The high and persistent level of NO exhibits cytotoxic action mediated by the production of reactive nitrogen species that lead to protein, cell and tissue damage (Coleman, 2001; Napoli et al., 2010). The overall effects of high NO are detrimental, including hypotension, pro-oxidant properties, apoptosis, and mediation of the effects of cytokines (Napoli et al., 2010).

## **Kinins**

Kinins are potent peptide hormones formed de novo in body fluids and tissues during inflammation. They are derived from kininogens through proteolytic cleavage by kallikrein. Three types of kinins have been identified in humans: BK, kallidin and met-lys-BK. The actions of kinins are mediated by activation of two main BK receptor subtypes, the inducible (B1) and constitutive (B2) receptors (White, 1999; Blais Jr. et al., 2000; Abraham et al., 2006).

BK elicits responses that mimic all the cardinal signs of inflammation (redness, swelling, heat and pain) (Blais Jr. et al., 2000) related to B2 receptors. In chronic inflammatory processes, B1 receptor plays an important role (Costa-Neto et al., 2008). BK causes vasodilatation, increased vascular permeability and smooth muscle contraction. Its vasodilator action is partly as a result

of generation of PGI<sub>2</sub> and release of NO. It is a potent pain-producing agent, and its action is potentiated by PGs (Campbell, 2003; Rang et al., 2003).

## **Cytokines**

Cytokines are low molecular weight intercellular signaling soluble proteins or polypeptides mediators synthesized and released by cells of the immune system during inflammation (Delves and Roitt, 2002; Verri Jr. et al., 2006). More than 100 cytokines have been identified, and includes interleukins, chemokines, interferons, colony-stimulating factors, growth factors and TNFs (Rang et al., 2003). They are produced by a variety of cell types, including macrophages, monocytes, mast cells, eosinophils and lymphocytes at inflammatory sites (Gabay and Kushner, 1999; Choy and Panayi, 2001).

Cytokines play roles in both acute and chronic inflammation exerting pro- or anti-inflammatory actions (Feghali and Wright, 1997; Kular et al., 2011). Among cytokines, IL-1, TNF- $\alpha$ , IFN- $\gamma$ , IL-12, IL-18 and granulocyte-macrophage colony-stimulating factor are inflammatory, whereas IL-4, IL-10, IL-13, IFN- $\alpha$  and TGF- $\beta$  are anti-inflammatory cytokines (Inagaki-Ohara et al., 2003).

Of the inflammatory cytokines, IL-1 ( $\alpha$  and  $\beta$ ) and TNF- $\alpha$  are extremely potent inflammatory molecules and are the primary mediators of septic shock (Feghali and Wright, 1997) and play pivotal role in the pathogenesis of rheumatoid arthritis (Lavagno et al., 2004). In addition, they are important cytokines in inducing the formation of other cytokines (Rang et al., 2003). For example: TNF- $\alpha$  induces IL-1, IL-6, IL-8, and GM-CSF (Choy and Panayi, 2001). Cytokines such as IL-1, IL-6, and TNF- $\alpha$  also induce PLA<sub>2</sub>, COX-2 and iNOS enzymes (Cirino, 1998). Endothelial ICAM-1 and VCAM-1 expression is also increased by inflammatory cytokines, such as IL-1 $\beta$  or TNF- $\alpha$  (Ley, 2008).

Chemokines are also termed as chemotactic cytokines, which are released by leukocytes and other cells that regulate the transit of leukocytes from blood into tissues (Lewis and Manning, 1999; Delves and Roitt, 2002). Each type of leukocyte bears chemokine receptors that guide it to particular chemokines in the tissue (Delves and Roitt, 2002). In addition, chemokines also

have other cytokine-like activities, including regulation of angiogenesis, proliferation and apoptosis (Bonecchi et al., 2008). Chemokines are thought to provide the directional cues for the movement of leukocytes in development, homeostasis and inflammation (Luster, 1998).

### **1.1.3. Anti-inflammatory Drugs**

#### **Non Steroidal Anti-inflammatory Drugs**

Non-steroidal anti-inflammatory drugs (NSAIDs) (such as, aspirin, ibuprofen, diclofenac) have been successfully used for the alleviation of pain, fever, and inflammation for many years and continue to be used daily by millions of patients worldwide (Rao et al., 2010; Vonkeman and van de Laar, 2010). NSAIDs are mainly indicated for mild to moderate pain and rheumatoid arthritis. Other indications include osteoarthritis, soft-tissue injury, renal colic, postoperative pain, and dental procedures (Vonkeman and van de Laar, 2010). The main mechanism of action of these drugs is believed to be the inhibition of the COX enzymes (COX-1 and COX-2) and consecutively the conversion of AA to PGs (Laine, 2002).

NSAIDs are well tolerated for short periods, but long-term administration may result in persistent adverse events (Quan et al., 2008). However, their use is limited by serious side effects, most common of which is gastroduodenal toxicity (Vonkeman and van de Laar, 2010). Other common adverse event is related to the kidneys i.e. acute renal insufficiency (Ziltener et al, 2010).

Since 1999, much attention has been directed to COX-2 selective inhibitors. COX-2 selective inhibitors (e.g. celecoxib, rofecoxib, valdecoxib, etoricoxib, lumircoxib) are class of NSAIDs that are used to treat rheumatoid and osteoarthritis, and other arthritic diseases, dental and surgical pain in post-operative settings, dysmenorrhoea, and acute injuries (Rainsford, 2007; Vonkeman and van de Laar, 2010). It has been observed that COX-2-selective NSAIDs could decrease the incidence of gastric and duodenal ulcers (Laine, 2002) by approximately 50 percent as compared with traditional NSAIDs (Quan et al., 2008). However, COX-2 inhibitors are associated with increased risk of cardiovascular events such as coronary thrombosis and stroke (Ward, 2008; Leitch et al., 2009).

## **Glucocorticoids**

Glucocorticoids (corticosteroids or steroids) are the most effective anti-inflammatory agents available for many inflammatory and immune diseases including, asthma, rheumatoid arthritis, inflammatory bowel disease, and other autoimmune diseases (Barnes, 2006; Barnes and Adcock, 2009).

Glucocorticoids are able to bind with the cortisol receptors and trigger various biological effects (Quan et al., 2008). Although there are several mechanisms by which glucocorticoids reduce inflammation, a major one could be to reduce expression of cytokine-induced genes (Dinarello, 2010). Glucocorticoids inhibit the expression of pro-inflammatory cytokines such as IL-1, IL-2, IL-6, IL-8, TNF- $\alpha$  and IFN- $\gamma$ . They also inhibit the generation of inflammatory mediators PGs, TXs, LTs and NO by suppression of gene expression of PLA<sub>2</sub>, COX-2, iNOS (Pfeilschifter and Mühl, 1999). Further, they alter recruitment and activation of inflammatory cells such as, monocytes, macrophages, eosinophils or lymphocytes (Pfeilschifter and Mühl, 1999; Spies et al., 2010).

The adverse effects of glucocorticoids occur in different organs and the severity ranges from slightly cosmetic aspects to serious disabling and even life threatening situations. Systemic application of glucocorticoids usually causes more severe side effects than topical application. Some of the common side effects include osteoporosis, adrenal insufficiency, cataract, skin atrophy, peptic ulcers and risk of infection (Quan et al., 2008).

## **Anti-cytokine Drugs**

Numerous cytokines play a critical role in many inflammatory diseases. Several strategies have been implemented to target these protein mediators such as the use of soluble monoclonal antibodies to bind the cytokines and/or receptor antagonists (Lewis and Manning, 1999).

***TNF- $\alpha$  antagonists:*** TNF- $\alpha$  is a pleiotropic cytokine with both pro-inflammatory and immune-regulatory functions (Taylor, 2010). Thus, blockade of TNF- $\alpha$  has great importance in reduction of inflammation in different inflammatory diseases (Dinarello, 2010).

Currently there are three TNF- $\alpha$  inhibitors infliximab, etanercept and adalimumab that have been approved for treatment of different inflammatory diseases. All three of these TNF- $\alpha$  antagonist have shown significant and clinically relevant improvements in rheumatoid arthritis, Crohn's disease, moderate to severe psoriasis, ankylosing spondylitis and ulcerative colitis (Dinarello, 2010; Silva et al., 2010).

***IL antagonists:*** IL-1 is a pro-inflammatory cytokine involved in arthritis. IL-6 is another pleiotropic inflammatory cytokine that has role in inflammation and hematopoiesis (Choy and Panayi, 2001). Two drugs, anakinra (IL-1 antagonist) and tocilizumab (IL-6 antagonist) are the current available agents (Dinarello, 2010) used for the treatment of rheumatoid and juvenile arthritis (Simmons, 2006).

### **Others**

Antihistamines (H<sub>1</sub> antagonists) are the current drugs that are used to treat allergic rhinitis (and other allergic diseases). Commonly used antihistamines are loratadine, cetirizine, and fexofenadine as these drugs are less sedating and more selective H<sub>1</sub> blocker than earlier first generation antihistamines (Kay, 2001; Ward and O'Neill, 2003).

LT antagonists are another group of anti-inflammatory drugs which consist of the LOX inhibitors such as zileuton, and the cysLT receptor antagonists, such as montelukast and zafirlukast. These drugs are given to treat both rhinitis and asthma. They are effective in patients with mild to moderate asthma (Tattersfield et al., 2002; Rang et al., 2003).

### **Future Anti-inflammatory Agents**

Neither the standard drugs nor the newer generations are without their shortcomings. Given the limitations of these agents, there remains a clear need for identification and validation of new anti-inflammatory drug targets (Ward, 2008). Some of the possible targets may include the following:

***NO-NSAIDs:*** currently, the main focus of hybrid NO-NSAIDs development is to reduce the adverse effects observed with traditional NSAID (Quan et al., 2008). In the gastrointestinal

tract, NO is known to exert its protective role by increasing the mucous secretion, mucosal blood flow and inhibition of neutrophil aggregation (Rao et al., 2010). Clinical studies showed that NaproCINOD, an NO releasing derivative of naproxen, reduces adverse effects of NSAIDs including selective COX-2 inhibitors (Fiorucci, 2009).

***PLA<sub>2</sub> inhibitors:*** PLA<sub>2</sub> is a key enzyme in the production of diverse mediators of inflammatory conditions (Quan et al., 2008). Inhibition of PLA<sub>2</sub> reduces production of oxidative products of AA (Buckle and Hedgecock, 1997). Several indole-based inhibitors of PLA<sub>2</sub> have been developed. Varespladib was developed as a treatment for rheumatoid arthritis and atherosclerosis and is under recent phase II trial (Rao et al., 2010). Another PLA<sub>2</sub> inhibitor LY333013 is in early phase clinical trial for treatment of arthritis (Quan et al., 2008).

***Dual COX/5-LOX inhibitors:*** Drugs able to inhibit both COXs and 5-LOX have been designed in order to obtain compounds that retain the activity of classical NSAIDs while avoiding undesirable adverse effects. These compounds prevent pro-inflammatory and gastrointestinal damaging effects of LTs (Bertolini et al., 2001). ML3000 is the most potent and well balanced dual inhibitor of COX/5-LOX is now in clinical Phase III (Fiorucci et al., 2001).

***PDE4 inhibitors:*** PDE4 is a major cyclic AMP-hydrolyzing enzyme in inflammatory and immunomodulatory cells. Inhibitors of PDE4 are anti-inflammatory and immunosuppressive agents. They cause inhibition of cellular trafficking and micro-vascular leakage, cytokine and chemokine release, reactive oxygen species production, and cell adhesion molecule expression (Sanz et al., 2005; Dinarello, 2010). These agents are currently under development for the treatment of asthma and chronic obstructive pulmonary disease (Spina, 2008). Rolipram, roflumilast, piclamilast, and pentoxifylline are in clinical use (Dinarello, 2010). Cilomilast is under phase II and III clinical trials. Others such as oglemilast and IPL512602 are currently in development (Spina, 2008). PDE4 inhibitors are also potential for the treatment of a number of other conditions such as allergic rhinitis, inflammatory bowel disease, atopic dermatitis, rheumatoid arthritis, and multiple sclerosis (Sanz et al., 2005).

***Anti-adhesion agents:*** cell adhesion molecules (such as, integrins, selectins) are key mediators of inflammatory processes and are attractive targets for discovery of novel therapeutic agents

(Szekanecz and Koch, 2004; Simmons, 2005). These molecules are important to ingress leukocytes into sites of inflammation (Szekanecz and Koch, 2004). Different compounds are targeting these adhesion molecules. The monoclonal antibody efalizumab, which binds the CD11a adhesion molecule, has been approved in some countries for the treatment of psoriasis. Natalizumab is anti-very late antigen-4 monoclonal antibody that showed great promise in the treatment of multiple sclerosis (Simmons, 2005; Simmons, 2006). Isis 2302 is other anti-adhesion compound which targets ICAM-1. There were positive data in Phase II trials for ulcerative colitis and these trials are continuing (Szekanecz and Koch, 2004; Simmons, 2005).

## **1.2. Medicinal Plants**

The vast majority of people on this planet still rely on traditional medicine (TM) for their everyday health care needs (Gurib-Fakim, 2006). Plant medicines are the most popular traditional remedies (World Health Organization, 2008). It is known that many countries in Africa, Asia and Latin America rely on TM to meet some of their primary health care needs (World Health Organization, 2002). It is estimated that about 80% of the world's population primarily those of developing countries rely on plant-derived medicines for their healthcare needs (Gurib-Fakim, 2006). In many developed countries popular use of traditional/complementary and alternative medicine is also expanded due to great concern about the adverse effects of modern drugs (World Health Organization, 2002).

TM has been practiced in Ethiopia since long time ago. It is estimated that about 80% of the Ethiopian population is still dependent on TM, which essentially involves the use of medicinal plants (Giday et al., 2007). This might be due to the cultural acceptability of healers and local pharmacopeias, the relatively low cost of TM and difficult access to modern health facilities (Kassaye et al., 2006). The prevalence of the use of plant medicines in self-care was found to be 12.5% in rural central Ethiopia (Gedif and Hahn, 2003).

Despite an apparent lack of scientific evidence for the quality, safety and efficacy, African indigenous herbal medicines are widely used throughout the African continent (Salawu et al., 2008). Scientific evaluation and validation of traditional medicinal plants is, however, essential for their possible utilization or in elimination of harmful practices (Makonnen et al., 2003a).

Medicinal plants constitute a source of raw materials for both traditional and modern medicine. They are distributed worldwide, but they are most abundant in tropical countries (Gurib-Fakim, 2006). Medicinal plants are still indispensable source of medicaments in the contemporary health care delivery system (Abay, 2009). It is estimated that approximately one quarter of the best selling drugs worldwide were natural products or derived from natural products (Balunas and Kinghorn, 2005). In the case of certain classes of pharmaceuticals, such as anti-tumor and antimicrobial medicines, this percentage may be as high as 60% (Robinson and Zhang, 2011). Currently, 119 drugs of modern medicines are derived from 90 plants, of which 74% are from plants used in TM. Currently used modern drugs such as quinine, artemisinin derivatives, digoxin glycosides, tubocurarine, aspirin etc are good examples of drugs from plant medicine (Gurib-Fakim, 2006).

### **1.2.1. Plants with Anti-inflammatory Activity**

The employment of anti-inflammatory agents may be helpful in the therapeutic treatment of those pathologies associated with inflammatory reactions (Sosa et al., 2002). Non-steroidal or steroidal anti-inflammatory drugs are commonly used to treat different inflammatory diseases (Yonathan et al., 2006; Boakye-Gyasi et al., 2008). However, the side effects of the currently available anti-inflammatory drugs pose a major problem in their clinical use (Tapiero et al., 2002; Yonathan et al., 2006). Attention is being given to the investigation of the efficacy of traditionally used plants as they are affordable and have fewer adverse effects (Adedapo et al., 2008; Saeed et al., 2010).

Since ancient times people have used phytochemicals found in plants to curtail the inflammatory process (Maroon et al., 2010). Some common plant medicines used to treat inflammation include: *Matricaria chamomilla* L. *Arnica montana* L., *Salix alba* (White Willow), *Glycyrrhiza glabra* (Shah et al., 2011), *Curcumin* (Turmeric), *pycnogenol* (maritime pine bark), *Boswellia serrata* resin (Frankincense), *Uncaria tomentosa* (Cat's Claw) (Maroon et al., 2010), *Cheilanthes farinose* (Yonathan et al., 2006), *Rosa abyssinica* Lindley, *Salvia nilotica* Juss (Sewuye and Asres, 2008), and *Clematis simensis* Fresen (Tadele et al., 2009).

The anti-inflammatory activities of plants are due to the secondary metabolites. These bioactive compounds consist of polyphenols, flavonoids, alkaloids, terpenoids, steroids, carotenoids, coumarins, curcumines etc (Saeed et al., 2010). Some of these secondary metabolites responsible for the anti-inflammatory activity are discussed briefly below.

### **Alkaloids**

In recent years, a large number of different kinds of naturally occurring alkaloids with anti-inflammatory activity have been reported (Calixto et al., 2000; Marzouk et al., 2010). For example: berberine, berbamine, palmatine, oxyacanthine, magnoflorine, and columbamine isolated from the roots of Turkish *Berberis* species (Kupeli et al., 2002), fangchinoline and tetrandrine from *Stephania tetrandrae* roots (Gautam and Jachak, 2009), achyranthine from *Achyranthes aspera* L. (Singh et al., 2008), isoretuline from *Strychnos henningsii* Gilg (Calixto et al., 2000), pseudo-akuammigine from *Picralima nitida* (Dowiejua et al., 2003), and theacrine from *Camellia kucha* (Wang et al., 2010) showed anti-inflammatory activity in different models of inflammation.

### **Terpenoids**

There are a number of plant derived terpenoids which exhibit distinctive pharmacological properties. Among other action, naturally occurring terpenoids have anti-inflammatory activity (Calixto et al., 2000). Some of them include: the sesquiterpene glucosides from methanol extract of *Taraxacum officinale* roots (Talhouk et al., 2007), triptolide from *Tripterygium wilfordii* (Talhouk et al., 2007; Gautam and Jachak, 2009), parthenolide from *Tanacetum parthenium* (Sobota et al., 2000), andrographolide from *Andrographis paniculata* (Singh et al., 2008), polygodial sesquiterpene from the bark of *Drymis winteri* (Da Cunha et al., 2001), and sesquiterpene lactone isolated from the methanolic extract of *Sphaeranthus indicus* (Fonseca et al., 2011).

## Flavonoids

Flavonoids are polyphenolic compounds that occur ubiquitously in plants and have a variety of biological effects. They have been found to have antimicrobial, antiviral, anti-ulcerogenic, cytotoxic, anti-neoplastic, antioxidant, anti-hepatotoxic, antihypertensive, hypolipidemic, antiplatelet, anti-inflammatory and analgesic activities. Flavonoids also have biochemical effects, which inhibit a number of enzymes such as aldose reductase, xanthine oxidase, phosphodiesterase, Ca<sup>2+</sup>-ATPase, PL, LOX, COX (Nijveldt et al., 2001; Rathee et al., 2009), and protein kinases (Manthey, 2000).

Different flavonoids with anti-inflammatory activity have been reported. The three flavonoids; 3-O-methylquercetin, 3,7-O-dimethylquercetin and 3,7-O-dimethylkaempferol from the ethanol extract of *Cistus laurifolius* L. (Küpelı and Yesilada, 2007); quercetin and dihydroquercetin from *Proustia pyrifolia* (Delporte et al., 2005); kaempferol-3,7-o- $\alpha$ -dirhamnoside and quercetin-3,7-o- $\alpha$ -dirhamnoside from leaves of *Tilia argentea* (Toker et al., 2004), baicalin from *Scutellaria baicalensis* Georgi (Li et al., 2000), nepetin, jaceosidin and hispidulin isolated from dichloromethane extract of *Eupatorium arnottianum* Griseb. (Clavin et al., 2007) exhibited anti-inflammatory effect.

### 1.3. *Ocimum suave*

One of the traditionally used plants believed to have anti-inflammatory component (s) is *Ocimum suave*. The genus *Ocimum*, a member of the Lamiaceae family, contains 200 species of herbs and shrubs. This species has a long history as culinary herbs, its foliage adding a distinctive flavor to many foods. It is also a source of aroma compounds and essential oils containing biologically active constituents (Hakkim et al., 2008).

*Ocimum suave* Willd is a plant belonging to the family Lamiaceae, syn.: Labiatae. The plant is found in tropical Asia and in West and East Africa where its geographical distribution is limited to mountainous areas (Tan et al., 2002). *Ocimum suave*, whose Oromifa name is “Anchabi”, is distributed in different regions of Ethiopia at a latitudinal range of 1600–2000 m above sea level (Makonnen et al., 2003b). *Ocimum suave* is one of the traditionally used plants

to relieve pain, fever and inflammatory disorders in Ethiopia. The mode of administration usually involves squeezing the fresh leaves and sniffing the juice, drinking or inhaling after boiling in water (Makonnen et al., 2003a). It is also used in traditional medicine for treatment of wounds in Uganda (Hassan et al., 2011) and for ulcers in East Africa (Tan et al., 2008). The Maandi, Koongo and Sundi peoples of Congo Brazzaville use the leaves of *Ocimum suave* in combination with other plants to treat fever in children, menstrual problems, stomach ache and broncho-pneumonic affections (Tan et al., 2008).

Phytochemical screening of both ethanol and aqueous extracts has revealed the presence of phenolic acids, flavonoids, glycosides and sugars as major chemical constituents (Makonnen et al., 2003b). Preliminary studies have also shown a high presence of triterpenes (Tan et al., 2008). Many volatile oil components either phenyl propane derivatives or terpenoids, including methyl eugenol, 1, 8-cineole, camphor, bornyl acetate, germacrene-D, E-myroxide, germacrene-B, caryophyllene oxide and p-cymene have been identified (Runyoro et al., 2010).

Different scientific and pharmacological studies have been carried out on the plant *Ocimum suave*. Both the aqueous and ethanol leaves extracts of *Ocimum suave* showed analgesic activity using tail flick and hot plate (Makonnen et al., 2003a) as well as writhing method (Debella et al., 2003). Aqueous and ethanol leaves extracts of *Ocimum suave* also exhibited antipyretic activity in yeast induced fever (Makonnen et al., 2003b). Other studies showed that the leaves of *Ocimum suave* to possess gastric cytoprotective antiulcer effects on acute gastric ulcer (Tan et al., 2002) and healing effects on chronic acetic acid-induced gastric ulcers (Tan et al., 2005). Further studies also showed the mosquito repellent (Seyoum et al., 2002), antimicrobial (Runyoro et al., 2010) and wound healing activity (Hassan et al., 2011) of *Ocimum suave*.

Acute and sub chronic toxicity as well as teratogenic effects of the aqueous extract of the leaves of *Ocimum suave* were also evaluated in mice and rats. Following acute and sub chronic administration, the extract was well tolerated and neither produced overt signs of clinical toxicity nor any signs of hepato, nephro or haemato-toxicity. Teratogenic effects were also absent (Tan et al., 2008).

Though *Ocimum suave* is traditionally employed to relieve inflammatory disease conditions, it has not been confirmed scientifically. The present study was, therefore, carried out to justify the traditional use of the plant for inflammation.

## **2. OBJECTIVE**

### **2.1. General Objective**

The purpose of this study was to evaluate the anti-inflammatory activities of the crude extracts (ethanol and aqueous) and fractions (butanol and water residue) of the most active extract of *Ocimum suave* at different doses in mice.

### **2.2. Specific Objectives**

- ✓ To evaluate the anti-inflammatory activity of aqueous and ethanol extracts of *Ocimum suave* using carrageenan inflammatory model.
- ✓ To evaluate the anti-inflammatory activity of the fractions (butanol and water residue) of the most active extract of *Ocimum suave* using carrageenan, histamine and serotonin inflammatory models.
- ✓ To get idea on the onset and duration of anti-inflammatory action of the plant

### **3. MATERIALS AND METHODS**

#### **3.1. Materials**

##### **3.1.1. Collection of Plant Materials**

The leaves of *Ocimum suave* were collected from Jimma about 324 Km South West of Addis Ababa in January 2011. The plant was identified by a taxonomist and voucher specimens representing *Ocimum suave* (Herbarium No. 001) was deposited at the National Herbarium, Department of Biology, Addis Ababa University, Ethiopia.

##### **3.1.2. Chemicals and Solvents**

Carrageenan (Sigma chemical company, Lot 55H188), histamine dihydrochloride (Aldrich chemical company, batch No 16925PA), serotonin creatinine sulphate (BDH laboratory supplies), ethanol, n-butanol (India), chloroform (Research-Lab fine chemicals, batch No 30480601, Mumbai), acetylsalicylic acid (Zhong shangground, batch No.0605026, China) were employed for the experiment.

##### **3.1.3. Experimental Animals**

The experiments were performed on in-house bred albino male and female mice (weighing 20-30g), which were obtained from the Ethiopian Health and Nutrition Research Institute, Department of Pharmacology, School of Medicine, Addis Ababa University and Aklilu Lemma Institute of Pathobiology, Addis Ababa University. They were all acclimatized to the animal house prior to use. Mice were kept in cages in animal house with a 12 h light: 12 h dark cycle. They fed on pellets and tap water *ad libitum*. The care and handling of mice were in accordance with the internationally accepted standard guidelines for use of animals.

## **3.2. Methods**

### **3.2.1. Preparation of Crude Extract**

Three hundred grams of air dried and powdered leaves of *Ocimum suave* were macerated in 70% (V/V) ethanol for 72 hrs. After filtration, the extracts were then concentrated under vacuum in a rotary evaporator to give 8.53% (w/w) gummy residue. Four hundred and fifty grams of powdered leaves of the above plant were also separately macerated with cold water and lyophilized after filtration to give 10.15% (w/w) powdered residue. The extracts were kept in tightly stoppered bottles and stored in a dessicator for future use.

### **3.2.2. Preparation of Solvent Fractions**

After anti-inflammatory screening test of the crude extracts, the most active extract i.e. aqueous extract was further fractionated using solvents: chloroform, butanol, and water. Fifty two grams of aqueous extract was taken and dissolved in warm distilled water. After filtration, the dissolved extract was added in a separatory funnel and mixed with 50 ml of chloroform three times. After shaking, it was allowed to stay for some time until complete formation of two layers. Then the lower layer i.e. chloroform was collected. After collecting the chloroform layer, 50 ml of butanol was successively added three times in the left aqueous residue and then the upper layer (butanol) was taken. Finally, the chloroform and butanol fractions were concentrated under vacuum in a rotary evaporator to give 0.67% (w/w) and 2.61% (w/w) gummy residue, respectively and the aqueous residue was lyophilized to give 17.31% (w/w) dried fraction. The fractions were kept in tightly stoppered bottles and stored in a dessicator till use. Based on the pilot experiment performed before commencing the actual experiments, butanol and water fractions were selected.

### **3.2.3. Testing Anti-inflammatory Activity**

#### **3.2.3.1. Carrageenan-induced Paw Edema**

In vivo anti-inflammatory activity was evaluated on the basis of inhibition of carrageenan-induced mouse hind paw edema as previously described by Yonathan *et al.*, (2006). Mice were

fasted for 12 hrs with free access to water before used for the experiments. Fourteen groups of mice of both sexes were used in this experiment and each group was composed of six mice (three male and three female). The first six groups received 400, 600 and 800mg/Kg of ethanol and aqueous extracts, while the other six groups were treated with 50, 100 and 200mg/Kg of butanol and water fractions. The remaining two groups received 200mg/Kg aspirin and normal saline that served as positive and negative controls, respectively. All the treatments were by oral gavage. A dose of 0.05 ml of 1% carrageenan in normal saline was injected into the sub-plantar surface of the left hind paw 30 minutes after the oral administration of the test substances, the standard and the vehicle. The volumes of injected paws were measured before, and 1, 2, 3, 4, 5 hrs after injection of carrageenan by plethysmographic method using Ugo-basile plethysmometer.

The increase in paw volume, i.e. inflammation was calculated according to the equation given by Delporte *et al.*, (2005) and expressed in percentage:

$$\%I = \frac{V_f - V_i}{V_i} \times 100$$

Where,  $V_i$  is the volume of paw before carrageenan injection and  $V_f$  is the volume of paw after carrageenan injection at a given time.

In addition, the anti-inflammatory effect was calculated according to the formula given below Delporte *et al.*, (2005) and expressed in percentage:

$$\%A = \frac{\%Ic - \%Ie}{\%Ic} \times 100$$

Where  $\%Ic$  and  $\%Ie$  are the mean inflammation values reached in control and experimental groups, respectively.

### **3.2.3.2. Histamine-induced Paw Edema**

Mice were administered with the test substances (butanol and aqueous fractions), standard and vehicle as described in section 3.2.3.1. In this model edema of the left hind paw of the mouse

was induced by sub-plantar injection of 0.05 ml of 1% freshly prepared histamine as described by Gupta *et al.*, (2006).

### **3.2.3.3. Serotonin-induced Paw Edema**

Same procedure as described in sections 3.2.3.1 and 3.2.3.2 were followed except use of serotonin instead of carrageenan and histamine.

### **3.2.4. Statistical Analysis**

The results were expressed as mean  $\pm$  S.E.M. Statistical analysis of the data was analyzed using Students t - test. Results with  $P < 0.05$  were considered statistically significant.

## 4. RESULTS

### 4.1. Effects of *Ocimum suave* on Carrageenan-induced Paw Edema

The ethanol and aqueous extracts of the leaves of *Ocimum suave* reduced carrageenan-induced paw edema at all doses employed and both extracts showed dose-dependent anti-inflammatory effects (table 1). The smallest dose of the ethanol extract, 400mg/Kg, significantly reduced carrageenan-induced paw volume ( $P<0.05$ ) at the 4 hour after administration. Ethanol extract at 600mg/Kg and 800mg/Kg, however, significantly reduced carrageenan-induced paw volume starting 1<sup>st</sup> hour after administration as compared to the control ( $P<0.05$ ) (Table 1).

As shown in table 1, the aqueous extract reduced paw volume significantly at the dose of 400mg/Kg ( $P<0.05$ , and at the 3<sup>rd</sup> hour of administration,  $P<0.01$ ). The result also showed that dose of 600mg/Kg significantly decreased paw edema ( $P<0.05$  at the 1<sup>st</sup>, 4<sup>th</sup> and 5<sup>th</sup> hours, and  $P<0.01$  at 2<sup>nd</sup> and 3<sup>rd</sup> hours). The highest dose of aqueous extract, 800mg/Kg, also produced significantly higher reduction in carrageenan-induced paw volume ( $P<0.01$  at the 1<sup>st</sup> hour and  $P<0.001$  at the rest of the hours) as compared to the control group (table 1).

Table 1: Effects of oral ethanol and aqueous extracts of *Ocimum suave* on carrageenan-induced mouse paw edema.

| Group           | Dose (mg/Kg) | Mean Inflammation (%I) $\pm$ S.E.M |                                    |                                    |                                    |                                    |
|-----------------|--------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|
|                 |              | 1h                                 | 2h                                 | 3h                                 | 4h                                 | 5h                                 |
| Normal saline   |              | 55.74 $\pm$ 4.31                   | 71.33 $\pm$ 4.86                   | 72.90 $\pm$ 4.06                   | 68.36 $\pm$ 5.32                   | 62.41 $\pm$ 5.53                   |
| Aspirin         | 200          | 33.49 $\pm$ 4.01 <sup>xb</sup>     | 40.63 $\pm$ 1.56 <sup>xa</sup>     | 45.79 $\pm$ 2.07 <sup>xa</sup>     | 38.01 $\pm$ 3.40 <sup>xa</sup>     | 32.03 $\pm$ 3.33 <sup>xa</sup>     |
| Ethanol extract | 400          | 44.77 $\pm$ 3.03 <sup>yc</sup>     | 57.42 $\pm$ 4.62 <sup>yb</sup>     | 61.10 $\pm$ 6.66                   | 52.28 $\pm$ 4.85 <sup>xc, yc</sup> | 50.98 $\pm$ 7.97 <sup>yb</sup>     |
|                 | 600          | 41.35 $\pm$ 4.53 <sup>xc</sup>     | 53.53 $\pm$ 2.98 <sup>xc, yb</sup> | 55.36 $\pm$ 5.30 <sup>xc</sup>     | 51.15 $\pm$ 3.83 <sup>xc, yc</sup> | 45.54 $\pm$ 3.14 <sup>xc, yc</sup> |
|                 | 800          | 40.87 $\pm$ 2.00 <sup>xc</sup>     | 52.76 $\pm$ 3.29 <sup>xc, yc</sup> | 55.35 $\pm$ 1.59 <sup>xb, yb</sup> | 49.77 $\pm$ 3.96 <sup>xc, yc</sup> | 43.27 $\pm$ 4.51 <sup>xc</sup>     |
| Aqueous extract | 400          | 40.67 $\pm$ 3.79 <sup>xc</sup>     | 53.53 $\pm$ 3.19 <sup>xc, yb</sup> | 54.72 $\pm$ 3.15 <sup>xb, yc</sup> | 49.01 $\pm$ 4.24 <sup>xc</sup>     | 43.41 $\pm$ 5.07 <sup>xc</sup>     |
|                 | 600          | 39.44 $\pm$ 4.52 <sup>xc</sup>     | 50.81 $\pm$ 4.23 <sup>xb</sup>     | 54.72 $\pm$ 3.15 <sup>xb</sup>     | 48.12 $\pm$ 4.87 <sup>xc</sup>     | 40.60 $\pm$ 5.86 <sup>xc</sup>     |
|                 | 800          | 33.72 $\pm$ 3.02 <sup>xb</sup>     | 40.26 $\pm$ 4.56 <sup>xa</sup>     | 43.99 $\pm$ 4.23 <sup>xa</sup>     | 37.43 $\pm$ 4.13 <sup>xa</sup>     | 30.66 $\pm$ 3.86 <sup>xa</sup>     |

<sup>x</sup>: relative to control, <sup>y</sup>: relative to standard: <sup>a</sup> $P<0.001$ , <sup>b</sup> $P<0.01$ , <sup>c</sup> $P<0.05$ .

The anti-inflammatory activities of ethanol and aqueous extract were shown in table 2. The ethanol and aqueous extract at a dose of 800 mg/kg oral exhibited maximum anti-inflammatory activity (30.67% and 50.87%, respectively) at the end of the 5<sup>th</sup> hour of administration (table 2). Although the ethanol extract produced lower effects than that of the standard drug, aspirin, high doses of aqueous extract were able to show comparable anti-inflammatory activities. The anti-inflammatory activity of aqueous extract at a dose of 800mg/Kg was a bit higher than aspirin (50.87% vs 48.68%) (Table 2). Greater paw edema inhibition was also observed by the aqueous extract than the ethanol one at 600 and 800mg/Kg dose levels.

Table 2: Anti-inflammatory activities of ethanol and aqueous extracts of *Ocimum suave* in comparison with that of aspirin on carrageenan-induced mouse paw edema.

| Group           | Dose (mg/Kg) | Anti-inflammatory activity (%A) |       |       |       |       |
|-----------------|--------------|---------------------------------|-------|-------|-------|-------|
|                 |              | 1h                              | 2h    | 3h    | 4h    | 5h    |
| Normal saline   |              | —                               | —     | —     | —     | —     |
| Aspirin         | 200          | 39.91                           | 43.04 | 37.19 | 44.39 | 48.68 |
| Ethanol extract | 400          | 19.68                           | 19.51 | 16.18 | 23.52 | 18.31 |
|                 | 600          | 25.82                           | 24.95 | 24.06 | 25.17 | 27.03 |
|                 | 800          | 26.68                           | 26.03 | 24.07 | 27.19 | 30.67 |
| Aqueous extract | 400          | 27.04                           | 24.95 | 24.94 | 28.31 | 30.44 |
|                 | 600          | 29.24                           | 28.77 | 25.89 | 29.61 | 34.95 |
|                 | 800          | 39.50                           | 43.56 | 39.66 | 45.24 | 50.87 |

Effects of the fractions of the aqueous extract on carrageenan-induced paw edema were shown in table 3 and 4. The butanol and water fractions reduced carrageenan-induced paw edema at all dose levels employed. As shown in table 3, dose dependent anti-inflammatory effects were observed for both fractions. The butanol fraction significantly decreased carrageenan-induced paw edema ( $P<0.05$ ) at 4<sup>th</sup> and 5<sup>th</sup> hours at a dose of 50mg/Kg. At a dose of 100mg/Kg the butanol fraction also reduced paw volume significantly ( $P<0.01$ ) at the 2<sup>nd</sup> and the 5<sup>th</sup> hours and ( $P<0.001$ ) at the 3<sup>rd</sup> and the 4<sup>th</sup> hours). Significant reduction of edema was also observed

with 200mg/Kg butanol fraction at all time ( $P<0.05$  at 1<sup>st</sup> hour,  $P<0.01$  at 2<sup>nd</sup> and 5<sup>th</sup> hours, and  $P<0.001$  at 3<sup>rd</sup> and 4<sup>th</sup> hours) as compared to the control.

In similar manner, water residue at the smallest dose, 50mg/Kg, showed significant reduction of paw edema ( $P<0.05$  at 1<sup>st</sup> and 2<sup>nd</sup> hours,  $P<0.001$  at 3<sup>rd</sup>, 4<sup>th</sup> and 5<sup>th</sup> hours). It was also observed that 100mg/Kg and 200mg/Kg doses of water residue produced higher reduction of edema ( $P<0.01$  at 1<sup>st</sup> hour, and  $P<0.001$  at 2<sup>nd</sup>, 3<sup>rd</sup>, 4<sup>th</sup> and 5<sup>th</sup> hours) as compared to the control group.

It was also noted that the butanol fraction at 50 and 100mg/Kg produced significantly lower effect than aspirin on carrageenan-induced paw edema. However, the effect produced by 200mg/Kg butanol fraction and all doses of aqueous fraction were not significantly different from aspirin (Table 3).

Table 3: Effects of oral butanol and water fractions of *Ocimum suave* on carrageenan-induced mouse paw edema.

| Group            | Dose (mg/Kg) | Mean Inflammation (%I) ± S.E.M |                              |                          |                              |                              |
|------------------|--------------|--------------------------------|------------------------------|--------------------------|------------------------------|------------------------------|
|                  |              | 1h                             | 2h                           | 3h                       | 4h                           | 5h                           |
| Normal saline    |              | 47.41±1.20                     | 60.24±1.13                   | 74.04±1.66               | 64.04±1.78                   | 59.18±1.49                   |
| Aspirin          | 200          | 33.89±2.45 <sup>xb</sup>       | 37.70±2.70 <sup>xa</sup>     | 48.35±2.46 <sup>xa</sup> | 37.67±2.97 <sup>xa</sup>     | 35.50±2.56 <sup>xa</sup>     |
| Butanol fraction | 50           | 43.25±1.90 <sup>yc</sup>       | 54.31±3.11 <sup>yb</sup>     | 63.84±4.78 <sup>yc</sup> | 53.18±3.84 <sup>xc, yb</sup> | 47.69±3.85 <sup>xc, yc</sup> |
|                  | 100          | 42.76±2.24 <sup>yc</sup>       | 47.36±3.02 <sup>xb, yc</sup> | 53.73±2.14 <sup>xa</sup> | 45.81±1.64 <sup>xa, yc</sup> | 42.36±3.32 <sup>xb, yc</sup> |
|                  | 200          | 38.20±2.89 <sup>xc</sup>       | 42.47±3.54 <sup>xb</sup>     | 50.98±1.59 <sup>xa</sup> | 44.42±1.58 <sup>xa</sup>     | 40.59±3.44 <sup>xb</sup>     |
| Water residue    | 50           | 38.40±2.94 <sup>xc</sup>       | 47.73±3.74 <sup>xc</sup>     | 50.23±3.85 <sup>xa</sup> | 46.89±2.48 <sup>xa, yc</sup> | 40.42±2.37 <sup>xa</sup>     |
|                  | 100          | 35.03±3.01 <sup>xb</sup>       | 38.26±1.39 <sup>xa</sup>     | 46.87±2.32 <sup>xa</sup> | 41.59±2.69 <sup>xa</sup>     | 35.86±1.43 <sup>xa</sup>     |
|                  | 200          | 32.13±3.57 <sup>xb</sup>       | 37.57±3.51 <sup>xa</sup>     | 45.24±2.41 <sup>xa</sup> | 35.15±1.44 <sup>xa</sup>     | 31.56±1.78 <sup>xa</sup>     |

<sup>x</sup>: relative to control, <sup>y</sup>: relative to standard: <sup>a</sup> $P<0.001$ , <sup>b</sup> $P<0.01$ , <sup>c</sup> $P<0.05$ .

Table 4 shows the anti-inflammatory activity of butanol and water fraction. The water fraction exhibited higher inhibition of paw edema than the butanol fraction at high doses. The butanol fraction showed 19.42% at the 5<sup>th</sup> hour with 50mg/Kg, 28.47% at the 4<sup>th</sup> hour with 100mg/Kg,

and 31.41% at the 5<sup>th</sup> hour with 200mg/Kg as their peak anti-inflammatory activities. On the other hand, doses of 50, 100 and 200mg/Kg oral water fraction showed their maximum anti-inflammatory activity of 32.16% at the 3<sup>rd</sup> hour, 39.41% and 46.67% at the 5<sup>th</sup> hour, respectively. Paw edema inhibition of high doses of water fractions of *Ocimum suave* found to be comparable to that of aspirin.

Table 4: Anti-inflammatory activities of butanol and water fractions of *Ocimum suave* in comparison to that of aspirin on carrageenan-induced mouse paw edema.

| Group            | Dose (mg/Kg) | Anti-inflammatory activity (%A) |       |       |       |       |
|------------------|--------------|---------------------------------|-------|-------|-------|-------|
|                  |              | 1h                              | 2h    | 3h    | 4h    | 5h    |
| Normal saline    |              | —                               | —     | —     | —     | —     |
| Aspirin          | 200          | 28.52                           | 37.42 | 34.70 | 41.18 | 40.00 |
| Butanol fraction | 50           | 8.77                            | 9.84  | 13.78 | 16.96 | 19.42 |
|                  | 100          | 9.81                            | 21.38 | 27.43 | 28.47 | 28.42 |
|                  | 200          | 19.43                           | 29.49 | 31.15 | 30.64 | 31.41 |
| Water residue    | 50           | 19.00                           | 20.77 | 32.16 | 26.78 | 31.70 |
|                  | 100          | 26.11                           | 36.49 | 36.70 | 35.06 | 39.41 |
|                  | 200          | 32.23                           | 37.63 | 38.90 | 45.11 | 46.67 |

#### 4.2. Effects of *Ocimum suave* on Histamine-induced Paw Edema

The effects of different doses of butanol and water fractions of *Ocimum suave* on histamine-induced paw edema are presented in table 5 and 6. Mice treated with both fractions reduced edema induced by histamine in a dose dependent manner. The butanol fraction significantly decreased inflammation ( $P < 0.05$  at 4<sup>th</sup> hour and  $P < 0.01$  at 2<sup>nd</sup> and 3<sup>rd</sup> hours) at a dose level of 50mg/Kg. This fraction also showed significant reduction of edema volume ( $P < 0.05$  at 5<sup>th</sup> hour;  $P < 0.01$  at 2<sup>nd</sup> and 4<sup>th</sup> hours and  $P < 0.001$  at 3<sup>rd</sup> hour) at 100mg/Kg dose. Butanol fraction significantly reduced histamine-induced edema throughout the experiment ( $P < 0.01$  at 4<sup>th</sup> and 5<sup>th</sup> hours;  $P < 0.001$  at 1<sup>st</sup>, 2<sup>nd</sup>, 3<sup>rd</sup> hours) at 200mg/Kg as compared to the control.

On the other hand, all doses of the aqueous fraction significantly reduced histamine induced paw volume throughout the observation time. Aqueous fraction significantly reduced inflammation ( $P<0.01$  at 1<sup>st</sup>, 4<sup>th</sup>, 5<sup>th</sup> hours;  $P<0.001$  at 2<sup>nd</sup> and 3<sup>rd</sup> hours) at 50mg/Kg. The result also showed that 100mg/Kg water fraction significantly decreased histamine-induced inflammation ( $P<0.01$  at 4<sup>th</sup> and 5<sup>th</sup> hour;  $P<0.001$  at 1<sup>st</sup>, 2<sup>nd</sup>, 3<sup>rd</sup> hours). The highest dose, 200mg/Kg, reduced the increase in paw volume at the fifth hour ( $P<0.01$ ) and at the first, second, third and fourth hours ( $P<0.001$ ) as compared to the control.

The effect produced by 200mg/Kg butanol fraction and all doses of aqueous fraction were not significantly different from the standard drug throughout the experiment. However, the butanol fraction at 50 (at all hours except at 5<sup>th</sup> hour) and 100mg/Kg (at 1<sup>st</sup> hour) produced significantly lower effect than aspirin on histamine-induced paw edema (table 5).

Table 5: Effects of oral butanol and water fractions of *Ocimum suave* on histamine-induced mouse paw edema.

| Group            | Dose (mg/Kg) | Mean Inflammation (%I) ± S.E.M |                              |                              |                              |                          |
|------------------|--------------|--------------------------------|------------------------------|------------------------------|------------------------------|--------------------------|
|                  |              | 1h                             | 2h                           | 3h                           | 4h                           | 5h                       |
| Normal saline    |              | 45.73±1.20                     | 54.47±1.89                   | 48.08±2.16                   | 43.54±3.34                   | 40.22±3.45               |
| Aspirin          | 200          | 30.25±2.07 <sup>xa</sup>       | 31.67±2.66 <sup>xa</sup>     | 26.57±2.25 <sup>xa</sup>     | 24.11±2.49 <sup>xb</sup>     | 22.63±2.65 <sup>xb</sup> |
| Butanol fraction | 50           | 43.74±1.79 <sup>ya</sup>       | 39.95±2.57 <sup>xb, yc</sup> | 36.08±2.17 <sup>xb, yb</sup> | 32.80±2.58 <sup>xc, yc</sup> | 32.33±5.38               |
|                  | 100          | 40.54±3.72 <sup>yc</sup>       | 38.06±3.53 <sup>xb</sup>     | 32.35±2.47 <sup>xa</sup>     | 30.03±1.87 <sup>xb</sup>     | 29.32±3.25 <sup>xc</sup> |
|                  | 200          | 34.30±1.91 <sup>xa</sup>       | 34.11±3.24 <sup>xa</sup>     | 29.24±2.93 <sup>xa</sup>     | 26.95±3.18 <sup>xb</sup>     | 25.48±2.05 <sup>xb</sup> |
| Water residue    | 50           | 35.38±2.16 <sup>xb</sup>       | 34.09±2.90 <sup>xa</sup>     | 32.94±2.46 <sup>xa</sup>     | 29.54±1.53 <sup>xb</sup>     | 26.34±1.08 <sup>xb</sup> |
|                  | 100          | 32.80±2.21 <sup>xa</sup>       | 30.55±2.37 <sup>xa</sup>     | 28.63±2.06 <sup>xa</sup>     | 25.21±1.44 <sup>xb</sup>     | 22.11±1.70 <sup>xb</sup> |
|                  | 200          | 28.98±2.14 <sup>xa</sup>       | 28.68±3.70 <sup>xa</sup>     | 24.15±3.01 <sup>xa</sup>     | 22.42±2.72 <sup>xa</sup>     | 22.02±2.67 <sup>xb</sup> |

<sup>x</sup>: relative to control, <sup>y</sup>: relative to standard: <sup>a</sup> $P<0.001$ , <sup>b</sup> $P<0.01$ , <sup>c</sup> $P<0.05$ .

The anti-inflammatory activities of the fractions of *Ocimum suave* are shown in table 6. Doses of 100 and 200mg/Kg of the water fraction exhibited greater inhibition of paw edema than the butanol fraction. The paw edema inhibition of the highest dose, 200mg/Kg, of butanol fraction is comparable to the smallest dose, 50mg/Kg, of aqueous fraction. At a dose of 200mg/Kg peak

anti-inflammatory activities of 39.18% for butanol fraction and 49.77% for water fraction were observed at the 3<sup>rd</sup> hour. The anti-inflammatory activities of high doses of water fractions of *Ocimum suave* were found to be comparable to that of the standard, aspirin (table 6).

Table 6: Anti-inflammatory activities of butanol and water fractions of *Ocimum suave* in comparison to that of aspirin on histamine-induced mouse paw edema.

| Group            | Dose (mg/Kg) | Anti-inflammatory activity (%A) |       |       |       |       |
|------------------|--------------|---------------------------------|-------|-------|-------|-------|
|                  |              | 1h                              | 2h    | 3h    | 4h    | 5h    |
| Normal saline    |              | —                               | —     | —     | —     | —     |
| Aspirin          | 200          | 33.85                           | 41.86 | 44.74 | 44.63 | 43.73 |
| Butanol fraction | 50           | 4.53                            | 26.66 | 24.96 | 24.67 | 19.62 |
|                  | 100          | 11.35                           | 30.13 | 32.72 | 31.03 | 27.10 |
|                  | 200          | 24.99                           | 37.38 | 39.18 | 38.10 | 36.65 |
| Water residue    | 50           | 22.63                           | 37.42 | 31.49 | 32.15 | 34.51 |
|                  | 100          | 28.27                           | 43.91 | 40.45 | 42.10 | 45.03 |
|                  | 200          | 36.63                           | 47.35 | 49.77 | 48.51 | 45.25 |

#### 4.3. Effects of *Ocimum suave* on Serotonin-induced Paw Edema

Table 7 and 8 shows the time course of anti-inflammatory effects of fractions of the aqueous extract after sub-plantar injection of serotonin. Both the butanol and aqueous fractions of *Ocimum suave* decreased serotonin-induced paw edema in a dose dependent manner. Both fractions significantly reduced paw volume at all doses. The butanol fraction at 50mg/Kg ( $P<0.05$  at 5<sup>th</sup> hour), 100mg/Kg ( $P<0.05$  at 3<sup>rd</sup>, 4<sup>th</sup> and 5<sup>th</sup> hours) and 200mg/Kg ( $P<0.05$ ) significantly decreased inflammation induced by serotonin as compared to vehicle treated group.

Table 7 also showed that aqueous fraction significantly reduced serotonin-induced paw volume throughout the observation time. At a dose of 50mg/Kg, aqueous fraction significantly decreased paw edema ( $P<0.05$ ). It was also observed that 100mg/Kg and 200mg/Kg of the aqueous fraction produced a significant reduction of inflammation ( $P<0.01$ ). The anti-

inflammatory activities of high doses of water residue were comparable to that of the standard drug, aspirin (table 8).

The result also showed that the butanol fraction at 50 (at 1<sup>st</sup> and 2<sup>nd</sup> hours) and 100mg/Kg (at 1<sup>st</sup> hour) produced significantly lower anti-inflammatory effect than aspirin on serotonin-induced paw edema. The effect produced by 200mg/Kg butanol fraction and all doses of aqueous fraction were not, however, significantly different from the standard drug, aspirin throughout the observation time (table 7).

Table 7: Effects of oral butanol and water fractions of *Ocimum suave* on serotonin-induced mouse paw edema.

| Group            | Dose (mg/Kg) | Mean Inflammation (%I) ± S.E.M |                          |                          |                          |                          |
|------------------|--------------|--------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                  |              | 1h                             | 2h                       | 3h                       | 4h                       | 5h                       |
| Normal saline    |              | 36.41±2.55                     | 41.29±3.12               | 48.31±3.24               | 41.36±3.71               | 37.32±2.98               |
| Aspirin          | 200          | 25.78±1.16 <sup>xb</sup>       | 28.54±1.62 <sup>xb</sup> | 31.69±2.70 <sup>xb</sup> | 26.57±2.29 <sup>xb</sup> | 24.20±2.39 <sup>xb</sup> |
| Butanol fraction | 50           | 34.80±3.15 <sup>yc</sup>       | 37.27±2.53 <sup>yc</sup> | 41.28±4.09               | 33.86±4.75               | 29.32±1.79 <sup>xc</sup> |
|                  | 100          | 32.53±2.28 <sup>yc</sup>       | 34.75±2.38               | 37.48±2.56 <sup>xc</sup> | 31.37±1.44 <sup>xc</sup> | 28.64±2.19 <sup>xc</sup> |
|                  | 200          | 28.04±2.43 <sup>xc</sup>       | 30.79±2.27 <sup>xc</sup> | 36.75±2.47 <sup>xc</sup> | 30.54±2.22 <sup>xc</sup> | 27.27±1.87 <sup>xc</sup> |
| Water residue    | 50           | 29.09±2.00 <sup>xc</sup>       | 31.22±1.13 <sup>xc</sup> | 36.85±1.58 <sup>xc</sup> | 30.57±1.18 <sup>xc</sup> | 27.02±2.13 <sup>xc</sup> |
|                  | 100          | 25.90±0.58 <sup>xb</sup>       | 28.55±1.64 <sup>xb</sup> | 31.66±2.99 <sup>xb</sup> | 26.70±1.18 <sup>xb</sup> | 24.82±1.85 <sup>xb</sup> |
|                  | 200          | 24.97±1.42 <sup>xb</sup>       | 26.73±1.63 <sup>xb</sup> | 30.17±1.74 <sup>xb</sup> | 24.55±1.67 <sup>xb</sup> | 22.62±1.88 <sup>xb</sup> |

<sup>x</sup>: relative to control, <sup>y</sup>: relative to standard: <sup>a</sup>P < 0.001, <sup>b</sup>P < 0.01, <sup>c</sup>P < 0.05.

Higher anti-inflammatory activity was exhibited by the aqueous fraction at 100mg/Kg and 200mg/Kg dose levels as compared to that of the butanol fraction (table 8). The butanol and aqueous fractions at a dose of 200mg/Kg showed 26.93% at the 5<sup>th</sup> hour, and 40.64% at the 4<sup>th</sup> hour as their maximum anti-inflammatory activity, respectively (table 8).

Table 8: Anti-inflammatory activities of butanol and water fractions of *Ocimum suave* in comparison to that of aspirin on serotonin-induced mouse paw edema.

| Group            | Dose (mg/Kg) | Anti-inflammatory activity (%A) |       |       |       |       |
|------------------|--------------|---------------------------------|-------|-------|-------|-------|
|                  |              | 1h                              | 2h    | 3h    | 4h    | 5h    |
| Normal saline    |              | —                               | —     | —     | —     | —     |
| Aspirin          | 200          | 29.19                           | 30.88 | 34.40 | 35.76 | 35.16 |
| Butanol fraction | 50           | 4.42                            | 9.74  | 14.55 | 18.13 | 21.44 |
|                  | 100          | 10.66                           | 15.84 | 22.42 | 24.15 | 23.26 |
|                  | 200          | 22.99                           | 25.43 | 23.93 | 26.16 | 26.93 |
| Water residue    | 50           | 20.10                           | 24.39 | 23.72 | 26.09 | 27.59 |
|                  | 100          | 28.87                           | 30.85 | 34.46 | 35.44 | 33.49 |
|                  | 200          | 31.42                           | 35.26 | 37.55 | 40.64 | 39.39 |

## 5. DISCUSSION

In the present study, anti-inflammatory effects of ethanol and aqueous extract, and fractions of the most active extract i.e. aqueous extract of *Ocimum suave* were investigated after sub-plantar injection of carrageenan, histamine and serotonin in mouse paw.

This study showed that the crude extracts (ethanol and aqueous) and fractions (butanol and water) of *Ocimum suave* possess anti-inflammatory activities in mice model. The observation that the aqueous extract of *Ocimum suave* exhibited greater anti-inflammatory activity than the ethanol extract, more of the active principle (s) responsible for the anti-inflammatory activity might be present in higher concentration in the aqueous extract. In addition, greater paw edema inhibition of the water residue of the aqueous extract indicates that the active principle (s) might be more soluble in water than butanol.

The presence of edema is one of the prime signs of inflammation (Yonathan et al., 2006). It has been documented that carrageenan induced rat paw edema is suitable *in vivo* model to study anti-inflammatory drugs both steroidal and non-steroidal since it involves several mediators (Mequanint et al., 2011). This method was chosen for the present study since edema induced by carrageenan is the most prominent acute experimental model in search for new anti-inflammatory drugs (Yonathan et al., 2006). In addition, it is a method that has been frequently used to assess the anti-edematous effect of natural products (Panthong et al., 2007). Furthermore, carrageenan is devoid of apparent systemic effects and exhibits a high degree of reproducibility (Kale et al., 2007).

The local injection of carrageenan induces inflammatory reactions in two different phases (Carey et al., 2010). The initial phase, which occurs between 0 and 2.5 h after the injection of the phlogistic agent, has been attributed to the action of mediators such as histamine, 5-HT and BK on vascular permeability (Yonathan et al., 2006). It has been reported that histamine and 5-HT are mainly released during the first 1.5 h while BK is released within 2.5 h after carrageenan injection (Panthong et al., 2007). The late phase is a result of overproduction of PGs in tissues and may occur from 2.5 to 6 h post-carrageenan injection (Mequanint et al., 2011). This late phase appears to be the most interesting phase in terms of inflammatory

processes. Thus, the maximal vascular response as determined with leukocyte migration to the inflamed area, also reaches its maximum level in this phase. It is well established that PGs, by virtue of their activity as modulators of inflammatory responses, have a major role in the inflammatory mechanism (Panthong et al., 2007).

The carrageenan-induced hind paw edema in rat is known to be sensitive to COX inhibitors, but not to LOX inhibitors, and has been used to evaluate the effect of NSAIDs which primarily inhibit the COX involved in PGs synthesis. It has been demonstrated that the suppression of carrageenan-induced hind paw edema after the third hour correlates reasonably with therapeutic doses of most clinically effective anti-inflammatory agents (Panthong et al., 2007).

Based on the results of this study, both ethanol and aqueous extract and fractions (butanol and water) of aqueous extract of *Ocimum suave* were able to effectively inhibit the increase in paw volume during both phases of carrageenan-induced inflammation. This indicates that the active component (s) of the plant may suppress both early and late phases of inflammation perhaps by inhibiting the release and/or activity of the inflammatory mediators involved in carrageenan-induced paw edema. The anti-inflammatory activities of the fractions of the aqueous extract might be associated to their anti-histamine or anti 5-HT activities observed in this study as these fractions also suppressed histamine and 5-HT induced inflammation. The strong anti-inflammatory activity of *Ocimum suave*, thus, might be by interfering with histamine, 5-HT and PGs synthesis or activity.

Previous phytochemical investigation of ethanol and aqueous extracts has revealed the presence of phenolic acids, flavonoids, glycosides, sugars (Makonnen et al., 2003b; Tan et al., 2008) and triterpenes (Tan et al., 2008) as major chemical constituents. Flavonoids isolated from different medicinal plants have been shown to possess anti-oxidant and anti-inflammatory activities (Nijveldt et al., 2001; Havsteen, 2002) and the anti-inflammatory property of triterpenes was also reported (Gautam and Jachak, 2009). These different compounds, thus, may be responsible for the anti-inflammatory activity of *Ocimum suave*.

Both extracts and fractions of *Ocimum suave* showed persistent anti-inflammatory activity during the five hours observation time. This study may give hint about the onset and duration

of action of the extracts and fractions of the plant investigated. Though it is difficult to speculate the time of onset for anti-inflammatory activity, both aqueous and ethanol extracts of the leaf of *Ocimum suave* for analgesic activity showed rapid onset, i.e. starting from ten minutes (Makonnen et al., 2003a). The duration, however, seems to be fairly long. To get full pictures of their pharmacokinetic profiles, further investigation should be undertaken.

## 6. CONCLUSION AND RECOMMENDATION

In conclusion, this study has shown that ethanol and aqueous extract of *Ocimum suave* does possess significant anti-inflammatory activities with high doses of the aqueous extract being more active. In addition, the butanol and water fractions of the aqueous extract of *Ocimum suave* have been confirmed to exert anti-inflammatory activity in which the water residue produced higher anti-inflammatory activity. The results, thus, might support the traditional use of this plant in inflammatory process. Further investigation, however, should be pursued after isolation and characterization of the active principle (s) in order to come up with the active compound (s) responsible for the anti-inflammatory properties of the plant. Moreover, other studies should be performed to confirm the exact mechanism (s) and anti-inflammatory activity of the plant in chronic inflammatory models.

## REFERENCES

- Abay SM (2009). Ethiopian herbal medicine practice and the recognition with modern medicine. *Phcog Rev* **3**:44-47.
- Abraham WM, Scuri M, Farmer SG (2006). Peptide and non-peptide bradykinin receptor antagonists: Role in allergic airway disease. *Eur J Pharmacol* **533**:215-221.
- Adedapo AA, Sofidiya MO, Maphosa V, Moyo B, Masika PJ, Afolayan AJ (2008). Anti-inflammatory and analgesic activities of the aqueous extract of *Cussonia paniculata* stem Bark. *Rec Nat Prod* **2**:46-53.
- Aggarwal BB, Gehlot P (2009). Inflammation and cancer: how friendly is the relationship for cancer patients? *Curr Opin Pharmacol* **9**:351-369.
- Alamanos Y, Voulgari PV, Alexandros A, Drosos AA (2006). Incidence and prevalence of Rheumatoid Arthritis, based on the 1987 American College of Rheumatology Criteria: A systematic review. *Semin Arthritis Rheum* **36**:182-188.
- Balunas MJ, Kinghorn AD (2005). Drug discovery from medicinal plants. *Life Sci* **78**:431-441.
- Barnes PJ (2006). Corticosteroids: The drugs to beat. *Eur J Pharmacol* **533**:2-14.
- Barnes PJ, Adcock IM (2009). Glucocorticoid resistance in inflammatory diseases. *Lancet* **373**:1905-17.
- Bertolini A, Ottani A, Sandrini M (2001). Dual acting anti-inflammatory drugs: A reappraisal. *Pharmacol Res* **44**:437-450.
- Bishop A, Anderson JE (2005). NO signaling in the CNS: from the physiological to the pathological. *Toxicology* **208**:193-205.

- Blais Jr. C, Marceau F, Rouleau J, Adam A (2000). The kallikrein-kininogen-kinin system: lessons from the quantification of endogenous kinins. *Peptides* **21**:1903-1940.
- Blaise GA, Gauvin D, Gangal M, Authier S (2005). Nitric oxide, cell signaling and cell death. *Toxicology* **208**: 177-192.
- Boakye-Gyasi E, Woode E, Ainooson GK, Obiri DD, Ansah C, Duwejua M, Donkoh A (2008). Anti-Inflammatory and antipyretic effects of an ethanolic extract of *Palisota hirsuta* K. Schum roots. *Afr J Pharm Pharmacol* **2**:191-199.
- Bonecchi R, Borroni EM, Savino B, Buracchi C, Mantovani A, Locati M (2008). Non-signaling chemokine receptors: Mechanism of action and role in vivo. *J Neuroimmunol* **198**:14-19.
- Buckle DR, Hedgecock C (1997). Drug targets in inflammation and immunomodulation. *DDT* **2**: 325-332.
- Calder PC (2006). n – 3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. *Am J Clin Nutr* **83**:1505S-19S.
- Calixto JB, Beirith A, Ferreira J, Santos AR, Filho VC, Yunes RA (2000). Naturally occurring antinociceptive substances from plants. *Phytother Res* **14**:401-418.
- Campbell DJ (2003). The renin–angiotensin and the kallikrein–kinin systems. *Int J Biochem Cell Biol* **35**:784-791.
- Carey MW, Rao NV, Kumar BR, Mohan GK (2010). Anti-inflammatory and analgesic activities of methanolic extract of *Kigelia pinnata* DC flower. *J Ethnopharmacol* **130**:179-182.
- Chatterjee A, Catravas JD (2008). Endothelial nitric oxide (NO) and its pathophysiologic regulation. *Vascul Pharmacol* **49**:134-140.
- Choy R, Panayi GS (2001). Cytokine pathways and joint inflammation in Rheumatoid Arthritis. *N Engl J Med* **344**:907-916.

- Cirino G (1998). Multiple Controls in Inflammation. *Biochem Pharmacol* **55**:105-111.
- Clavin M, Gorzalczany S, Macho A, Muñoz E, Ferraro G, Acevedo C, Martino V (2007). Anti-inflammatory activity of flavonoids from *Eupatorium arnottianum*. *J Ethnopharmacol* **112**:585-589.
- Coleman JW (2001). Nitric oxide in immunity and inflammation. *Int Immunopharmacol* **1**:1397-1406.
- Costa-Neto CM, Dillenburg-Pilla P, Heinrich TA, Parreiras-e-Silva LT, Pereira M, Reis RI, Souza P (2008). Participation of kallikrein–kinin system in different pathologies. *Int Immunopharmacol* **8**:135-142.
- Coussens LM, Werb Z (2002). Inflammation and cancer. *Nature* **420**:860-867.
- Da Cunha FM, Frode TS, Mendes GL, Malherios A, Cechinel V, Yunes RA, Calixto JB (2001). Additional evidence for the anti-inflammatory and anti-allergic properties of the sesquiterpene pilygodial. *Life Sci* **70**:159-169.
- Dannhardt G, Kiefer W (2001). Cyclooxygenase inhibitors – current status and future prospects. *Eur J Med Chem* **36**:109-126.
- De las Heras B, Hortelano S (2009). Molecular basis of the anti-inflammatory effects of terpenoids. *Inflamm Allergy Drug Targets* **8**:28-39.
- Debella A, Makonnen E, Abebe D, Teka F, Kidanemariam AT (2003). Pain management in mice using the aqueous and ethanol extracts of four medicinal plants. *East Afr Med J* **80**: 435-439.
- Delporte C, Backhouse N, Erazo S, Negrete R, Vidal P, Silva X, L´opez-P´erez JL, San Feliciano A, Mu˜noz O (2005). Analgesic – anti-inflammatory properties of *Proustia pyrifolia*. *J Ethnopharmacol* **99**:119-124.
- Delves PJ, Roitt IM (2002). The immune system. *N Engl J Med* **343**:37-49.

- Dinarello CA (2010). Anti-inflammatory agents: Present and future. *Cell* **140**:935-950.
- Duwiejua M, Woode E, Obiri DD (2003). Pseudo-akuammigine, an alkaloid from *Picralima nitida* seeds, has anti-inflammatory and analgesic actions in rats. *J Ethnopharmacol* **81**: 73-79.
- Feghali CA, Wright TM (1997). Cytokines in acute and chronic inflammation. *Front Biosci* **2**: d12-26.
- Fiorucci S (2009). Prevention of non-steroidal anti-Inflammatory drug-induced ulcer: Looking to the future. *Gastroenterol Clin North Am* **38**:315-332.
- Fiorucci S, Meli R, Bucci M, Cirino G (2001). Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? *Biochem Pharmacol* **62**:1433-1438.
- Fonseca LC, Dadarkar SS, Lobo AS, Mishra PB, Thakkar AD, Chandrababu S, Padigar M (2011). NF- $\kappa$ B-mediated anti-inflammatory activity of the sesquiterpene lactone 7-hydroxyfrullanolide. *Eur J Pharmacol* **657**:41-50.
- Gabay C, Kushner I (1999). Acute - phase proteins and other systemic responses to inflammation. *N Engl J Med* **340**:448-454.
- Gautam R, Jachak SM (2009). Recent developments in anti-Inflammatory natural products. *Med Res Rev* **29**:767-820.
- Gedif T, Hahn H (2003). The use of medicinal plants in self-care in rural central Ethiopia. *J Ethnopharmacol* **87**:155-161.
- Giday M, Teklehaymanot T, Animut A, Mekonnen Y (2007). Medicinal plants of the Shinasha, Agew-awi and Amhara peoples in Northwest Ethiopia. *J Ethnopharmacol* **110**:516-525.
- Gupta M, Mazumder UK, Gomathi P, Selvan VT (2006). Anti-inflammatory evaluation of leaves of *Plumeria acuminata*. *BMC Complement Altern Med* **6**:36-42.

Gurib-Fakim A (2006). Medicinal plants: Traditions of yesterday and drugs of tomorrow. *Mol Aspects Med* **27**:1-93.

Haeggström JZ, Rinaldo-Matthis A, Wheelock CE, Wetterholm A (2010). Advances in eicosanoid research, novel therapeutic implications. *Biochem Bioph Res Commun* **396**:135-139.

Hailu S, Tessema T, Silverman M (2003). Prevalence of symptoms of asthma and allergies in school children in Gondar Town and its vicinity, Northwest Ethiopia. *Pediatr Pulmonol* **35**:427-432.

Hakkim FL, Arivazhagan G, Boopathy R (2008). Antioxidant property of selected *Ocimum* species and their secondary metabolite content. *J Med Plants Res* **2**:250-257.

Harizi H, Corcuff J, Gualde N (2008). Arachidonic-acid derived eicosanoids: roles in biology and immunopathology. *Trends Mol Med* **14**:461-469.

Harris SG, Padilla J, Koumas L, Ray D, Phipps RP (2002). Prostaglandins as modulators of immunity. *Trends Immunol* **23**:144-150.

Hassan KA, Deogratus O, Nyafuono JF, Francis O, Engeu OP (2011). Wound healing potential of the ethanolic extracts of *Bidens pilosa* and *Ocimum suave*. *Afr J Pharm Pharmacol* **5**:132-136.

Havsteen BH (2002). The biochemistry and medical significance of the flavonoids. *Pharmacol Ther* **96**:67-202.

Hseu Y, Wu F, Wu J, Chen J, Chang W, Lu F, Lai Y, Yang H (2005). Anti-inflammatory potential of *Antrodia camphorata* through inhibition of iNOS, COX-2 and cytokines via the NF- $\kappa$ B pathway. *Int Immunopharmacol* **5**:1914-1925.

Huwiler A, Pfeilschifter J (2009). Lipids as targets for novel anti-inflammatory therapies. *Pharmacol Ther* **124**:96-112.

Inagaki-Ohara K, Hanada T, Yoshimura A (2003). Negative regulation of cytokine signaling and inflammatory diseases. *Curr Opin Pharmacol* **3**:435-442.

Jadidi-Niaragh F, Mirshafiey A (2010). Histamine and histamine receptors in pathogenesis and treatment of multiple sclerosis. *Neuropharmacology* **59**:180-189.

Kale M, Misar AV, Dave V, Joshi M, Mujumdar AM (2007). Anti-inflammatory activity of *Dalbergia lanceolaria* bark ethanol extract in mice and rats. *J Ethnopharmacol* **112**:300-304.

Kassaye KD, Amberbir A, Getachew B, Mussema Y (2006). A historical overview of traditional medicine practices and policy in Ethiopia. *Ethiop J Health Dev* **20**:127-134.

Kay AB (2001). Allergy and allergic diseases. *N Engl J Med* **344**:30-37, 109-113.

Kular L, Pakradouni J, Kitabgi P, Laurent M, Martinerie C (2011). The CCN family: A new class of inflammation modulators? *Biochimie* **93**:377-388.

Küpelı E, Koşar M, Yeşilada E, Hüsnü K, Başer C (2002). A comparative study on the anti-inflammatory, antinociceptive and antipyretic effects of isoquinoline alkaloids from the roots of Turkish *Berberis* species. *Life Sci* **72**:645-57.

Küpelı E, Yesilada E (2007). Flavonoids with anti-inflammatory and antinociceptive activity from *Cistus laurifolius* L. leaves through bioassay-guided procedures. *J Ethnopharmacol* **112**:524-30.

Laine L (2002). The Gastrointestinal effects of non-selective NSAIDs and COX-2-Selective inhibitors. *Semin Arthritis Rheum* **32**:25-32.

Laroux FS, Lefer DJ, Kawachi S, Scalia R, Cockrell AS, Gray L, Van der Heyde H, Hoffman JM, Grisham MB (2000). Role of nitric oxide in the regulation of acute and chronic Inflammation. *Antiox Redox Signal* **2**:391-396.

Lavagno L, Gunella G, Bardelli C, Spina S, Fresu LG, Viano I, Brunelleschi S (2004). Anti-inflammatory drugs and tumor necrosis factor- $\alpha$  production from monocytes: role of

transcription factor NF- $\kappa$ B and implication for rheumatoid arthritis therapy. *Eur J Pharmacol* **501**:199-208.

Leitch AE, Haslett C, Rossi AG (2009). Cyclin-dependent kinase inhibitor drugs as potential novel anti-inflammatory and pro-resolution agents. *Br J Pharmacol* **158**:1004-1016.

Lewis AJ, Manning AM (1999). New targets for anti-inflammatory drugs. *Curr Opin Chem Biol* **3**:489-494.

Ley K (2008). The Microcirculation in Inflammation. In: Tuma RF, Durán WN and Ley K (eds), *Microcirculation*, 2<sup>nd</sup> edn, Academic Press, USA, pp 387-448.

Li BQ, Fu T, Gong W, Dunlop N, Kung H, Yan Y, Kang J, Wang JM (2000). The flavonoid baicalin exhibits anti-inflammatory activity by binding to chemokines. *Immunopharmacology* **49**:295-306.

Luster AD (1998). Chemokines – chemotactic cytokines that mediate inflammation. *N Engl J Med* **338**:436-445.

MacGlashan D (2003). Histamine: A mediator of inflammation. *J Allergy Clin Immunol* **112**:S53-59.

Makonnen E, Debella A, Abebe D, Teka F (2003a). Analgesic properties of some Ethiopian medicinal plants in different models of nociception in mice. *Phytother Res* **17**:1108-1112.

Makonnen E, Debella A, Zerihun L, Abebe D, Teka F (2003b). Antipyretic properties of the aqueous and ethanol extracts of the leaves of *Ocimum suave* and *Ocimum lamiifolium* in mice. *J Ethnopharmacol* **88**:85-91.

Manthey JA (2000). Biological properties of flavonoids pertaining to inflammation. *Microcirculation* **7**:S29-34.

Mantovani A, Allavena P, Sica A, Balkwill F (2008). Cancer-related inflammation. *Nature* **454**:436-444.

- Maroon JC, Bost JW, Maroon A (2010). Natural anti-inflammatory agents for pain relief. *Surg Neurol Int* **1**:80.
- Marzouk B, Marzouk Z, Haloui E, Fenina N, Bouraoui A, Aouni M (2010). Screening of analgesic and anti-inflammatory activities of *Citrullus colocynthis* from southern Tunisia. *J Ethnopharmacol* **128**:15-19.
- Medzhitov R (2008). Origin and physiological roles of inflammation. *Nature* **454**:428-435.
- Mequanint W, Makonnen E, Urga K (2011). In vivo anti-inflammatory activities of leaf extracts of *Ocimum lamiifolium* in mice model. *J Ethnopharmacol* **134**:32-36.
- Mody GM (2008). Challenges in the management of Rheumatoid Arthritis in developing countries. *Best Pract Res Clin Rheumatol* **22**:621-641.
- Napoli C, Crimi E, Williams-Ignarro S, de Nigris F, Ignarro LJ (2010). Nitric Oxide, Oxidative Stress, Immune Response and Critical Care. In: Ignarro LJ (ed), *Nitric Oxide: Biology and Pathobiology*, 2<sup>nd</sup> edn, Academic Press, USA, pp.755-772.
- Nathan C (2002). Points of control in inflammation. *Nature* **420**:846-852.
- Nijveldt RJ, Van Nood E, Van Hoorn DEC, Boelens PG, Van Norren K, Van Leeuwen PA (2001). Flavonoids: a review of probable mechanisms of action and potential applications. *Am J Clin Nutr* **74**:418-25.
- Omoigui S (2007). The Biochemical Origin of Pain – Proposing a new law of Pain: The origin of all pain is inflammation and the inflammatory response – A unifying law of pain. *Med Hypotheses* **69**: 70-82.
- Panthong A, Supraditaporn W, Kanjanapothi D, Taesotikul T, Reutrakul V (2007). Analgesic, anti-inflammatory and venotonic effects of *Cissus quadrangularis* Linn. *J Ethnopharmacol* **110**:264-270.

- Passani MB, Blandina P (2011). Histamine receptors in the CNS as targets for therapeutic intervention. *Trends Pharmacol Sci* **32**:242-249.
- Pfeilschifter J, Mühl H (1999). Immunopharmacology: anti-inflammatory therapy targeting transcription factors. *Eur J Pharmacol* **375**:237-245.
- Quan L, Thiele GM, Tian J, Wang D (2008). The development of novel therapies for Rheumatoid Arthritis. *Expert Opin Ther Pat* **18**:723-738.
- Rådmark O, Samuelsson B (2010). Regulation of the activity of 5-lipoxygenase, a key enzyme in leukotriene biosynthesis. *Biochem Bioph Res Commun* **396**:105-110.
- Rainsford KD (2007). Anti-inflammatory drugs in the 21st Century. *Subcell Biochem* **42**:3-27.
- Rang P, Dale M, Ritter J, Moore PK (2003). *Pharmacology*, 5<sup>th</sup> edn, Churchill Livingstone, p.217-241.
- Rao P, Kabir SN, Mohamed T (2010). Non-steroidal anti-Inflammatory drugs (NSAIDs): Progress in small molecule drug development. *Pharmaceuticals* **3**:1530-1549.
- Rathee P, Chaudhary H, Rathee S, Rathee D, Kumar V, Kohli K (2009). Mechanism of action of flavonoids as anti-inflammatory agents: a review. *Inflamm Allergy Drug Targets* **8**:229-35.
- Redington AE (2006). Modulation of nitric oxide pathways: Therapeutic potential in asthma and chronic obstructive pulmonary disease. *Eur J Pharmacol* **533**: 263-276.
- Robinson MM, Zhang X (2011). Traditional medicines: Global situation, issues and challenges. World Health Organization, Geneva.
- Rolin S, Masereel B, Dogné J (2006). Prostanoids as pharmacological targets in COPD and asthma. *Eur J Pharmacol* **533**:89-100.
- Rosenberg R, Vinker S, Zakut H, Kizner F, Nakar S, Kitai E (1999). An unusually high prevalence of asthma in Ethiopian immigrants to Israel. *Fam Med* **31**: 276-279.

Runyoro D, Ngassapa O, Vagionas K, Aliyiannis N, Graikou K, Chinou I (2010). Chemical composition and antimicrobial activity of the essential oils of four *Ocimum* species growing in Tanzania. *Food Chem* **119**: 311-316.

Saeed MK, Deng Y, Dai R, Li W, Yu Y, Iqbal Z (2010). Appraisal of antinociceptive and anti-inflammatory potential of extract and fractions from the leaves of *Torreya grandis* Fort Ex. Lindl. *J Ethnopharmacol* **127**:414-418.

Salawu OA, B. Chindo A, Tijani AY, Adzu B (2008). Analgesic, anti-inflammatory, antipyretic and anti-plasmodial effects of the methanolic extract of *Crossopteryx febrifuga*. *J Med Plants Res* **2**:213-218.

Sanz MJ, Cortijo J, Morcillo EJ (2005). PDE4 inhibitors as new anti-inflammatory drugs: Effects on cell trafficking and cell adhesion molecules expression. *Pharmacol Ther* **106**:269-297.

Schneider E, Rolli-Derkinderen M, Arock M, Dy M (2002). Trends in histamine research: new functions during immune responses and hematopoiesis. *Trends Immunol* **23**:25-263.

Schwab JM, Serhan CN (2006). Lipoxins and new lipid mediators in the resolution of inflammation. *Curr Opin Pharmacol* **6**:414-420.

Scott DL, Wolfe F, Huizinga T WJ (2010). Rheumatoid Arthritis. *Lancet* **376**:1094-1108.

Serhan CN (2008). Systems approach with inflammatory exudates uncovers novel anti-inflammatory and pro-resolving mediators. *Prostaglandins Leukotrienes Essent Fatty Acids* **79**:157-163.

Serhan CN, Chiang N (2008). Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. *Br J Pharmacol* **153**: S200-S215.

Sewuye W, Asres K (2008). In vivo anti-inflammatory and anti-nociceptive activities of extracts of *Rosa abyssinica* and *Salvia nilotica*. *Ethiop Pharm J* **26**:75-82.

- Seyoum A, Kabiru EW, Lwande W, Killeen GF, Hassanali A, Knols BG (2002). Repellency of live potted plants against *Anopheles gambiae* from human baits in semi-field experimental huts. *Am J Trop Med Hyg* **67**:191-195.
- Shah BN, Seth AK, Maheshwari KM (2011). A review on medicinal plants as a source of anti-inflammatory agents. *Res J Med Plant* **5**:101-105.
- Silva L, Ortigosa L, Benard G (2010). Anti-TNF- $\alpha$  agents in the treatment of immune-mediated inflammatory diseases: Mechanisms of action and pitfalls. *Immunotherapy* **2**:817-833.
- Simmons DL (2005). Anti-adhesion therapies. *Curr Opin Pharmacol* **5**:398-404.
- Simmons DL (2006). What makes a good anti-inflammatory drug target? *DDT* **11**:210-219.
- Singh A, Malhotra S, Subban R (2008). Anti-inflammatory and analgesic agents from Indian medicinal plants. *Int J Integr Biol* **3**:57-72.
- Sobota R, Szwed M, Kasza A, Bugno M, Kordula T (2000). Parthenolide inhibits activation of signal transducers and activators of transcription (STATs) induced by cytokines of the IL-6 family. *Biochem Biophys Res Commun* **267**:329-333.
- Sosa S, Balic MJ, Arvigo R, Esposito RG, Pizza C, Altinier G, Tubaro A (2002). Screening of the topical anti-inflammatory activity of some Central American plants. *J Ethnopharmacol* **81**:211-215.
- Spies CM, Bijlsma J, Burmester G, Buttgerit F (2010). Pharmacology of glucocorticoids in Rheumatoid Arthritis. *Curr Opin Pharmacol* **10**:302-307.
- Spina D (2008). PDE4 inhibitors: current status. *Br J Pharmacol* **155**:308-315.
- Stables MJ, Gilroy DW (2011). Old and new generation lipid mediators in acute inflammation and resolution. *Prog Lipid Res* **50**:35-51.

- Szekanecz Z, Koch AE (2004). Therapeutic inhibition of leukocyte recruitment in inflammatory diseases. *Curr Opin Pharmacol* **4**:423-428.
- Tadele A, Asres K, Melaku D, Mekonnen W (2009). In vivo anti-inflammatory and anti-nociceptive activities of the leaf extracts of *Clematis simensis* Fresen. *Ethiop Pharm J* **27**:33-41.
- Talhok RS, Karam C, Fostok S, El-Jouni W, Barbour EK (2007). Anti-inflammatory bioactivities in plant extracts. *J Med Food* **10**:1-10.
- Talwara S, Nandakumara K, Nayaka PG, Bansala P, Mudgala J, Mora V, Rao CM, Lobo R (2011). Anti-inflammatory activity of *Terminalia paniculata* bark extract against acute and chronic inflammation in rats. *J Ethnopharmacol* **134**:323-328.
- Tan PV, Mezui C, Enow-Orock GE, Dimo T, Nyasse B (2005). Healing effect on chronic gastric ulcers and short-term toxicity profile of the leaf of methanol extract of *Ocimum suave* wild (Lamiaceae) in rats. *Afr J Tradit Complement Altern Med* **2**: 312-325.
- Tan PV, Mezui C, Enow-Orock GE, Njikam N, Dimo T, Bitolog P (2008). Teratogenic effects, acute and sub chronic toxicity of the leaf aqueous extract of *Ocimum suave* Wild (Lamiaceae) in rats. *J Ethnopharmacol* **115**: 232-237.
- Tan PV, Nyasse B, Dimo T, Mezui C (2002). Gastric cytoprotective anti-ulcer effects of the leaf methanol extract of *Ocimum suave* (Lamiaceae) in rats. *J Ethnopharmacol* **82**: 69-74.
- Tapiero H, Ba GN, Couvreur P, Tew KD, (2002). Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies. *Biomed Pharmacother* **56**:215-222.
- Tattersfield AE, Knox AJ, Britton JR, Hall IP (2002). Asthma. *Lancet* **360**:1313-22.
- Taylor PC (2010). Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. *Curr Opin Pharmacol* **10**:308-315.

Toker G, Kupeli E, Memisoglu M, Yesilada E (2004). Flavonoids with anti-nociceptive and anti-inflammatory activities from the leaves of *Tilia argenta* (silver linden). *J Ethnopharmacol* **95**:393-397.

Ulbrich H, Fiebich B, Dannhardt G (2002). Cyclooxygenase-1/2 (COX-1/COX-2) and 5-lipoxygenase (5-LOX) inhibitors of the 6, 7-diaryl-2, 3-1H-dihydropyrrolizine type. *Eur J Med Chem* **37**:953-959.

Venkatesha SH, Berman BM, Moudgil KD (2011). Herbal medicinal products target defined biochemical and molecular mediators of inflammatory autoimmune arthritis. *Bioorg Med Chem* **19**: 21-29.

Verri Jr. WA, Cunha TM, Parada CA, Poole S, Cunha FQ, Ferreira SH (2006). Hypernociceptive role of cytokines and chemokines: Targets for analgesic drug development? *Pharmacol Ther* **112**:116-138.

Vonkeman HE, van de Laar M (2010). Non-steroidal anti-Inflammatory drugs: Adverse effects and their prevention. *Semin Arthritis Rheum* **39**:294-312.

Wang Y, Yang X, Zheng X, Li J, Ye C, Song X (2010). Theacrine, a purine alkaloid with anti-inflammatory and analgesic activities. *Fitoterapia* **81**:627-631.

Ward SG (2008). New drug targets in inflammation: efforts to expand the anti-inflammatory armoury. *Br J Pharmacol* **153**:S5-S6.

Ward SG, O'Neill L (2003). Spotlight on new anti-inflammatory drug targets in the immune system. *Curr Opin Pharmacol* **3**:391-395.

Weiss U (2008). Inflammation. *Nature* **454**:427.

White M (1999). Mediators of inflammation and the inflammatory process. *J Allergy Clin Immunol* **103**:S378-81.

World Health Organization (2002). Traditional Medicine Strategy 2002–2005, Geneva.

World Health Organization (2008). Fact Sheet, Traditional medicine.

Yemaneberhan H, Bekele Z, Venn A, Lewis S, Parry E, Britton J (1997). Prevalence of wheeze and asthma and relation to atopy in urban and rural Ethiopia. *Lancet* **350**:85-90.

Yonathan M, Asres K, Assefa A, Bucar F (2006). In vivo anti-inflammatory and anti-nociceptive activities of *Cheilanthes farinose*. *J Ethnopharmacol* **108**:462-470.

Yoon J, Baek SJ (2005). Molecular targets of dietary polyphenols with anti-inflammatory properties. *Yonsei Med J* **46**:585-596.

Zhang M, Thurmond RL, Dunford PJ (2007). The histamine H<sub>4</sub> receptor: A novel modulator of inflammatory and immune disorders. *Pharmacol Ther* **113**:594-606.

Ziltener JL, Leal S, Fournier PE (2010). Non-steroidal anti-inflammatory drugs for athletes: An update. *Ann Phys Rehab Med* **53**:278-288.